JPH0220064B2 - - Google Patents
Info
- Publication number
- JPH0220064B2 JPH0220064B2 JP57123731A JP12373182A JPH0220064B2 JP H0220064 B2 JPH0220064 B2 JP H0220064B2 JP 57123731 A JP57123731 A JP 57123731A JP 12373182 A JP12373182 A JP 12373182A JP H0220064 B2 JPH0220064 B2 JP H0220064B2
- Authority
- JP
- Japan
- Prior art keywords
- fibrinopeptide
- acid addition
- addition salt
- reagent
- fpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 claims abstract description 98
- 101800000974 Fibrinopeptide A Proteins 0.000 claims abstract description 98
- 102400000525 Fibrinopeptide A Human genes 0.000 claims abstract description 98
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 17
- 238000003127 radioimmunoassay Methods 0.000 claims description 16
- 239000003146 anticoagulant agent Substances 0.000 claims description 15
- 229940127219 anticoagulant drug Drugs 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 108090000190 Thrombin Proteins 0.000 claims description 13
- 229960004072 thrombin Drugs 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- 108010039627 Aprotinin Proteins 0.000 claims description 6
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 6
- 239000000440 bentonite Substances 0.000 claims description 6
- 229910000278 bentonite Inorganic materials 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003868 thrombin inhibitor Substances 0.000 claims description 6
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 claims description 5
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 4
- 229960004405 aprotinin Drugs 0.000 claims description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000009137 competitive binding Effects 0.000 claims description 3
- 230000000636 anti-proteolytic effect Effects 0.000 claims description 2
- 239000002350 fibrinopeptide Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000013522 chelant Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 abstract description 2
- 238000003149 assay kit Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 101000693911 Equus caballus Albumin Proteins 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100025421 Serine protease inhibitor Kazal-type 6 Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CVMIVKAWUQZOBP-UHFFFAOYSA-L manganic acid Chemical compound O[Mn](O)(=O)=O CVMIVKAWUQZOBP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8114—Kunitz type inhibitors
- G01N2333/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
æ¬çºæã¯ããã€ããªãããããïŒä»¥åŸãæã
FPAãšåŒã¶ïŒã®æ¿åºŠã枬å®ããã©ãžãªã€ã ãã¢
ãã»ã€RIAæ³ããã®ãããªæ¹æ³ã«ãããŠå©çšãã
æååºè©Šè¬ãããã³ãã®ãããªæ¹æ³ã«ãããŠå©çš
ããè©Šè¬ãå«æããããã±ãŒãžãã¹ããããã«é¢
ããã çŸåšãååºç³»äžã®çš®ã ã®ç©è³ªã®åææ³ã«ã€ããŠ
èå³ãå¢å€§ããŠããããããã®ç©è³ªã®ãã¡ã®ïŒçš®
ããªãã¡ãFPAã¯ãè¶ ååºèœåïŒhypercoagua
bilityïŒã®æ瀺ãäžããã§ããããååºç³»ã«ãã
ãäžç³»åã®äºè±¡ã¯ããã®ããã»ã¹ã«ãããæåã®
äºè±¡ãšããŠFPAã解æŸãããããã€ããªãã²ã³
ãžã®ããã³ãã³ã®äœçšãçããããã以äžã®äœçš
ã¯ãã€ããªãããããã解æŸãããŠãã€ããªã
ã¢ãããŒãçæãããã®ã¢ãããŒã¯ä»ã®é µçŽ ã®å©
ãããããŠéåããŠäžæº¶æ§ã®ã¯ããããšãªãã FPAã®å®éã«çŸåšçšããããŠããå®éšå®€ã®ã
ã¹ãã¯ãäžé©åã§ãããH.L.NoselãéçºããïŒ
ã€ã®ãã®ãããªRIAãã¹ãã¯ãMeasurement of
FPA in Human BloodïŒããã®è¡æ¶²äžã®FPAã®
枬å®ïŒãJJ.clin.Invest.54ïŒ43â53ïŒ1974ïŒããã³
Potential Use of FPA Measurements in the
Diagnosis and Measurement of ThrombosisïŒ
è¡æ çã®èšºæããã³æž¬å®ã«ãããFPA枬å®ã®å¯
èœæ§ãå èµãã䜿çšïŒãThrombosïŒDiathesïŒ
haemorrh.ïŒStuttgïŒ33ïŒ426ïŒ1975ïŒäžã«èšèŒã
ããŠããããããã®äž¡è ã®æç®ãåŒçšãã€ãŠãã
ã«å ããããã®ãã¹ãã¯ãæ£åžžã®åŸªç°ãããã€ã
ãªãã²ã³ã®çŽ200ngïŒçŽ0.09ïŒ ïŒã®çäœå 転åã«çž
åœããè¡æŒ¿ã®ïŒmlåœã2ngã®FPAããå°éã®æ€åº
ãã§ãããããããªãããè©Šæã®åéããã³åã
æ±ãã¯éåžžã«é倧ã§ããããããŠFPAã¬ãã«ã®
誀ãŸã€ãå¢å ããã°ãã°èŠãããã æ¬çºæã®ç®çã¯ã絶ããäžå®ããä¿¡é Œæ§ã®ãã
çµæãæäŸãããè¡æŒ¿äžã®FPAã®RIAæé ãæ
äŸããããšã§ããã æ¬çºæã«ããã°ããŸãè¡æ¶²ã®è©Šæãéããããš
ãããªããè¡æŒ¿äžã®FPAã®çäœå€æ¿åºŠã枬å®ã
ã競åRIAæ³ã®æ¹è¯ãæäŸãããã次ãã§ãåèš
è©Šæäžã®ããã³ãã³ãæå¶éã®ããã³ãã³æå¶å€
ã§æå¶ãããããŠè¡æŒ¿ãåèšè©Šæããåé¢ããã
次ã«ãåèšè¡æŒ¿ã®è©Šæããã©ãžãªã€ã ãã¢ãã»ã€
競åçµåæ¡ä»¶äžã«ãååãªéã®FPAã«å¯Ÿããæ
äœããã³æŸå°æŽ»æ§ã§æ°·èããFPAãšæ¥è§Šããã
ãã®åŸè¡æŒ¿çµåFPAãçµåããªãFPAããåé¢
ãããããŠæŸå°æŽ»æ§ã枬å®ãããæ¹è¯ã¯ãããã³
ãã³ãæå¶ããããã«ããçš®ã®æå¶å€ã䜿çšãã
ããšãå«ãã æ¬çºæã®ä»ã®å®æœæ æ§ã¯ãæå¶å€ã®ïŒçš®ããã¬
ãŒãå€ããã³æã¿ã³ãã¯å解å€ãå«æãããRIA
æ³ã«ãããŠäœ¿çšããæååºè©Šè¬ã«é¢ããã æ¬çºæã®ä»ã®é¢ã¯ããã®ãããªRIAæ³ã«ãããŠ
å©çšããè©Šè¬ãå«æããããã±ãŒãžãã¹ãããã
ã«é¢ããã æ¬çºæã«ãããŠäœ¿çšã§ããããã³ãã³æå¶å€
ã¯ãäœçšãéããããªãã¡ãããã³ãã³ãã»ãšã
ã©ç¬éçã«ãããšãã°ã10ç§ããçããæéã§æ
å¶ããè¡æŒ¿äžã§å®å®ã§ããããªãã¡ãFPAãã»
ãšãã©ãŸãã¯ãŸã€ãã圢æããããé·æéå®å®ã§
ãããããªãã¡ã䜿çšåéåžžã®è²¯èµå¯¿åœãæãã
ãããŠããã³ãã³ã®æ¬è³ªçã«äžå¯éçæå¶å€ã§ã
ãããã®ãããªæå¶å€ã®ïŒçš®ã¯ãâããšãã«ã¢
ã©ãã«ââãããªã«âââãïŒâïŒïŒâã¯ã
ãâïŒâã¯ã¢ããããã¿ã³âïŒâãªã³ïŒãïŒä»¥åŸã
âPheâProâArgCh2ClãšåŒã¶ïŒããã³ãã®é©
åœãªå¡©é¡ãããšãã°ãããã³ãã³ãæå¶ããã€å
è¿°ã®æ§è³ªãããªãã¡ãäœçšãéããè¡æŒ¿äžã§å®å®
ã§ãããªã©ã®æ§è³ªãæããå¡©é¡ã§ããã é©åœãªå¡©é¡ã¯ã匷ããŸãã¯åŒ±ãç¡æ©ãŸãã¯ææ©
ã®é žé¡ããèªå°ãããé žä»å å¡©é¡ãå å«ãããé©
åœãªç¡æ©é žã®äŸã¯ãããã²ã³å«æé žãããšãã°ã
å¡©é žãããåæ°ŽçŽ é žãŸãã¯èåæ°ŽçŽ é žïŒãªã³å«æ
é žãããšãã°ããªã³é žãäºãªã³é žã次äºãªã³é žïŒ
ã€ãªãŠå«æé žãããšãã°ãç¡«é žã次äºç¡«é žãŸãã¯
ããªç¡«é žïŒããã³ä»ã®é žãããšãã°ãç¡é žãŸãã¯
ãã³ã¬ã³é žã§ãããé©åœãªææ©é žã®äŸã¯ãã®é žã
é ¢é žãã¯ããé ¢é žãã¯ãšã³é žãä¹³é žãé ç³é žãªã©
ã§ããã é žä»å å¡©ã¯ãé©åœãªé žãå«æãã氎溶液äžã«é
é¢å¡©åºã溶ããããããŠãã®æº¶æ¶²ãèžçºããããš
ã«ããå¡©ãåé¢ããããšã«ãã€ãŠããããã¯éé¢
å¡©åºãšéžæããé žãšãææ©æº¶åªäžã§åå¿ãããã
ãšã«ãã€ãŠã補é ããåŸè ã®å Žåã«ãããŠãå¡©ã¯
çŽæ¥åé¢ãããããã¯ãã®æº¶æ¶²ã®æ¿çž®ã«ããåŸã
ããšãã§ãããïŒåœéãŸãã¯ãã以äžã®é žã䜿çš
ãããšããå€é žä»å å¡©ãåŸããããã®å Žåååäž
ã«ïŒåããå€ãå¡©åºæ§çªçŽ ååãååšãããïŒåœ
éã®é žã䜿çšãããšããäžé žä»å å¡©ãåŸãããã âPheâProâArgâCh2Clã®HFé žä»å å¡©ã
ãã³éé¢å¡©åºã¯ãæè¿ã®åè¡ç©ãKetherïŒ
Thrombosis Research 14ïŒ969â993ïŒ1979ïŒã«
èšèŒãããŠããæé ã«åŸã€ãŠè£œé ã§ããã è¿°ã¹ãããã«ãæ¬çºæã®æ¹æ³ã®ç¬¬ïŒå·¥çšã¯ãè¡
液詊æãéããåèšè©Šæäžã®ããã³ãã³ãæå¶ã
ãããŠåèšè©Šæããè¡æŒ¿ãåé¢ããããšãããª
ãã è¡æ¶²è©Šæã¯ãéåžžã®æ段ãããšãã°ã20ã²ãŒãž
ã®éãçšããéèç©¿åºã«ããéããããšãã§ã
ããäžè¬ã«ãïŒã10mlã®è¡æ¶²ãéããã è¡æ¶²è©Šæã¯ãã®åŸç¬éçã«ãŸãã¯çŽã¡ã«æå¶é
ã®åè¿°ã®æå¶å€ã®ïŒçš®ãšåãããŠãåèšè©Šæäžã®
ããã³ãã³ãæå¶ãããããšãã°ãæå¶éã¯ãå š
è¡ã®ïŒmlåœããçŽ0.001mgã1.0mgã奜ãŸããã¯çŽ
0.04ãçŽ0.6mgã§ãããæå©ã«ã¯ãæå¶å€ãšäžç·
ã«ããã¬ãŒãåéãããšãã°ãå šè¡ã®ïŒmlåœãçŽ
ïŒmgãïŒmgã奜ãŸããã¯çŽ3.5ã4.5mgã®ãã¬ãŒã
å€ãããšãã°ããšãã¬ã³ãžã¢ãã³åé ¢é žEDTA
ãŸãã¯ãšãã¬ã³ã°ãªã³ãŒã«ãã¹ïŒïŒ¢âã¢ãããšã
ã«ãšãŒãã«ïŒïŒ®ïŒïŒ®ïŒNâ²ïŒNâ²âåé ¢é žïŒEGTAïŒ
ãŸãã¯ãããã®å¡©ãåãããããšã«ãã€ãŠãçäœ
å€ã®ããã³ãã³ã®çºçã¯å®è³ªçã«ãŸãã¯å®å šã«æ
å¶ããããéåžžãFPAã®ã¿ã³ãã¯å解ãå®è³ªç
ã«æžå°ãããããããã¯é²æ¢ããããã®æã¿ã³ã
ã¯å解å€ãæã¿ã³ãã¯å解éããšãã°ãå šè¡ã®ïŒ
mlåœãçŽ50ã300KIUïŒã«ãªã¯ã¬ã€ã³æå¶å€åäœïŒ
奜ãŸããã¯çŽ90ã150KIUã®éã§å ããããã®ã
ããªæã¿ã³ãã¯å解å€ã®äŸã¯ãTrasylolïŒã¢
ããããã³ïŒã§ãããæå©ã«ã¯ãæ¬çºæã®ããã³
ãã³æå¶å€ã®ïŒçš®ãšäžç·ã«ãã¬ãŒãå€ããã³æã¿
ã³ãã¯å解å€ã䜿çšããããšã«ãã€ãŠãåéã®å
é¡ã¯ææã«è»œæžãããããŠå®€æž©ã«ãããŠæ°æéã
ããšãã°ãïŒãïŒæéãïŒâã«ãããŠæ°æ¥éãã
ãšãã°ãïŒãïŒæ¥éããããŠâ20âã«ãããŠæ°ã«
æéãããšãã°ïŒãïŒã«æéãå®å®ãªè¡æŒ¿è©Šæã
åŸãããã ãã¹ãŠã®ïŒçš®é¡ã®ç©è³ªã¯ãæå©ã«ã¯ã氎溶液ã
ããšãã°ãå¡©åãããªãŠã ãŸãã¯ç·©è¡å€ã®æ°Žæº¶äž
ã§ã䟿å©ã«çµåããŠæååºè©Šè¬ã圢æã§ãããæ
ååºè©Šè¬ã¯ååãªéã®æå¶å€ããã¬ãŒãå€ããã³
æã¿ã³ãã¯å解å€ãå«æããããã«ããåã ã¯ã
æååºè©Šè¬ãè¡æ¶²ã«å ãããšãããã®æå³ããæ©
èœãçºæ®ãããéåžžãæ°Žæ§æååºè©Šè¬ã®åïŒmläž
ã«ãçŽ0.1mgãçŽïŒmgã奜ãŸããã¯çŽ0.4ãçŽ0.6mg
ã®æå¶å€ãååšããçŽ20mgãçŽ60mgã奜ãŸããã¯
çŽ35mgçŽ45mgã®ãã¬ãŒãå€ãååšãããããŠçŽ
500ãçŽ3000KIUïŒmgã奜ãŸããã¯çŽ900ãçŽ
1500KIUïŒmlã®æã¿ã³ãã¯è³ªå€ãååšãããè©Š
è¬ã¯æååºéã§äœ¿çšãããšãã°æ°Žæ§è©Šè¬ã¯ãå šè¡
ïŒmlåœããçŽ0.05ãçŽïŒmlã奜ãŸããã¯çŽ0.1ã
çŽ0.2mlã®éã§äœ¿çšãããè©Šè¬ã®PHã¯ãäžè¬ã«çŽ
ïŒãïŒã§ããã 次ã«ãè¡æŒ¿ãåžžæž©ã«ãããŠé å¿åé¢ããããšã«
ãããããšãã°ã1000ã15000Xgã«ãããŠãåå
æéãããšãã°ã20åéïŒâãŸãã¯å®€æž©ã«ãããŠ
é å¿åé¢ããããšã«ããã奜ãŸããã¯ãããã¯å
éåŸã§ããã ãéããã«å®æœãããåé¢ããè¡æŒ¿
ã¯é©åœãªæž©åºŠãããšãã°ã20â以äžã§ãæ¬çºæã«
åŸãRIAã¢ãã»ã€ã€ã«ãããŠäœ¿çšãããŸã§ã貯èµ
ããã RIAæé ã«ãããŠè¡æŒ¿ã䜿çšããåã«ãéåžžã
ããååŠçããŠæ©ããåå¿æ§ã®ãã€ããªãã²ã³ã
ãã³ãã€ããªã³ïŒãã€ããªãã²ã³ïŒæçãè¡æŒ¿ã
ãé€å»ããªããŠã¯ãªããªããããã¯åžžæ³ã«ãã
ãŠãããšãã°ãè¡æŒ¿ãã¢ã«ã³ãŒã«ã§æ²æ®¿ãããã
ãŠæ¶²ãéæããããšã«ãã€ãŠããããã¯ãã³ã
ãã€ããŸãã¯ä»ã®åæ§ãªäœçšç©è³ªãè¡æŒ¿ã«ååãª
éã§æ·»å ããŠåŠšå®³ç©è³ªãè¡æŒ¿ããé€å»ããããšã«
ãã€ãŠãå®æœã§ãããéåžžããã³ããã€ãã®ã¹ã©
ãªãŒãè¡æŒ¿æ··åç©ãžå ããã次ãã§ãè¡æŒ¿ãæ··å
ããæå°1200Xgã«ãããŠååãªæéãããšãã°ã
20åéé å¿åé¢ãããäžæŸãåãåºãããããŠã¢
ãã»ã€æ³ã«äœ¿çšããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒå·¥çšã¯ãRIAã¢ãã»ã€ã
RIA競çµåæ¡ä»¶äžã§åžžæ³ã«ãããŠãããšãã°ãå
è¿°ã®NOSSELåè¡ç©ã«èšèŒãããããã«ããŠã
å®æœããããšãããªããåºæ¬çã«ã¯ãããã¯åå
ãªéã®FPAã«å¯Ÿããæäœããã³æŸå°æŽ»æ§ã§æšè
ããFPAãè¡æŒ¿è©Šæã«å ãããã®åŸæäœçµåã
ãFPAãçµåããªãFPAããåé¢ãããããŠæŸ
å°æŽ»æ§ã枬å®ããããšãããªãã FPAæäœãšåå¿ããæŸå°æŽ»æ§ã§æšèããFPA
ã䜿çšã§ããã䟿å©ã«ã¯ãæŸå°æŽ»æ§ã§æšèããã
ã¹ã¢ããããã·ã«ãŒFPAé¯äœã䜿çšã§ãããã
ãã¯ãããšãã°ãâ125ãŸãã¯ä»ã®æŸå°æ§åäœ
äœã§ã¯ãã©ãã³ïŒŽæ³ãçšããŠæšèããããšãã§ã
ãããã®é¯äœã補é ãã詳现ãªæé ã¯ãåè¿°ã®
NOSSELåè¡ç©ã«ãããŠèŠãã ãããšãã§ããã äžè¬ã«ãFPAãâ125ãŸãã¯ä»ã®æŸå°æ§åäœ
äœã§çŽ800ãçŽ1600ãã€ã¯ãããŠãªãŒïŒãã€ã¯ã
ã°ã©ã ã®æ¯æŽ»æ§ã«æšèããããã®åäœäœæšè
FPAããã®åéã§ç¥ãããŠããããã«åžéããŠã
åå¿åªè³ªäžã§æäœãšçæ³çãªå ç«æž¬å®äŒåãè¡ã
ããšãã§ããåäœäœæšèè©Šè¬ããã³æé©ãªã¢ãã»
ã€æ床ãåŸãããšãã§ããããã®åžéã¯ãPHçŽïŒ
ã10ã®é©åœãªæ°Žæ§ç·©è¡æ¶²ãçšããŠå®æœã§ãããã
ã®åžéã«çšããããšãã§ããé©åœãªç·©è¡æ¶²ã¯ãã
ãªã¹ïŒTrisïŒãåæ¥çã«å ¥æã§ãããããªã¹ïŒã
ããããã·ã¡ãã«ã«ïŒã¢ããã¡ã¿ã³ãå«æããæ°Ž
溶液ïŒãã«ãã¿ãŒã«ãåæ¥çã«å ¥æã§ããïŒïŒïŒ
âãžãšãã«ãã«ããã«é žã®æ°Žæº¶æ¶²ããã³ä»ã®ãã
ç¥ãããç·©è¡æ¶²ã§ãããåžé床ã¯ãçšããå Žåã
åæã®æ¯æŽ»æ§ãããã³ææã®æé©ãªèšæ°ããã³ã¢
ãã»ã€ã®æ床ãå®çŸããããã«èŠããææã®åŽ©
å£ïŒåïŒDPMïŒã«äŸåãããã è¡æŒ¿ã®æªç¥ã®è©ŠæãæŸå°æŽ»æ§ã§æšèããFPA
è©Šè¬ãšæ··åããåŸãæäœãããšãã°ãFPAãšå
ç«åå¿ãããæäœãšæŸå°æŽ»æ§FPAãå«æããæ
äœæº¶æ¶²ãæ··åç©ãžå ãããæäœã¯FPAããã³æŸ
å°æŽ»æ§FPAã«å¯Ÿããç¹ç°æ§ãæãããããããŠã
æäœã®æå®éã«ãã€ãŠçµåãããæŸå°æŽ»æ§FPA
ã®éã¯æªç¥ã®è¡æŒ¿è©Šè¬ããã®æšèããªãFPAã®
ååšã§æžå°ãããããŠãã®å¹æã¯æšèããªã
FPAã®æ¿åºŠã«çŽæ¥é¢ä¿ããã ãã®åéã§æ¢ç¥ã®æ¹æ³ããFPAããã³æšè
FPAãšåå¿ãããæäœãåŸãããã«ããããšã
ã§ãããããšãã°ãæäœã¯å®¿äž»åç©ãããšãã°ã
ãŠãµã®ãæ¥çš®ããããšã«ãã€ãŠè£œé ããããšãã§
ãããæ¥çš®åŸãããæéãçµéããããã®é宿䞻
ã¯æäœãçæãã次ãã§æè¡æž ããã®åç©ããæŸ
åºãããŠæäœãåŸãããã®æäœããæŸå°æŽ»æ§ã§æš
èããFPAã®åžéã«äœ¿çšãããã®ã«é¡äŒŒããç·©
è¡ç©è³ªäžã«ãåžéããŠã¢ãã»ã€ã«ãããŠæé«ã®æ§
èœãåŸãæ¿åºŠã«ããŠç¬¬ïŒæäœè©Šè¬ã圢æãããã
ãšãã°ããã¬ãŒãµãŒéã®æŸå°æŽ»æ§FPAïŒ0.01ã
0.09CiïŒã®20ã80ïŒ ã奜ãŸããã¯30ã70ïŒ ãçµå
ããçšåºŠã«æè¡æž ãåžéããããšã奜ãŸãããæ
äœãè¡æŒ¿ã®æ··åç©ãžãã€ããå ãããšãåŸããã
æ··åç©ããæäœçµåFPAããã³çµåããªãFPA
ã®å®è³ªçãªå¹³è¡¡ãçæãã枩床ã«ãããŠååãªæ
éå¹é€ãããå¹é€æéäžãåžéãããæè¡æž äžã®
æäœã¯æŸå°æŽ»æ§FPAããã³FPAãšå ç«é¯äœã圢
æãããæ¬çºæã®å®æœã«ãããŠãå¹é€å·¥çšã¯çŽ15
ã37âã奜ãŸããã¯20ã30âã®æž©åºŠã§ã»ãŒ40ã
120åéã奜ãŸããã¯40åéå®æœããããšã奜ãŸ
ããããã®åŸæäœã«ããFPAã®çµåã¯å®è³ªçå¹³
è¡¡ã«å°éããããšãããã€ãã å¹é€å·¥çšãå®çµãããšããçµåããªãFPAã
æäœçµåFPAããåé¢ããã åé¢ã¯ãæšçããããã¯ã€ãªã³äº€ææš¹èããæ¬
質çã«æãèã®èãã¹ããªãããå å«ããåžžæ³ã«
ãã䟿å©ã«å®æœããããä»ã®åé¢æè¡ã¯ç¬¬ïŒæäœ
ã䜿çšããæè¡ã§ããããã®ç¬¬ïŒæäœã¯FPAã«
察ããŠç¹ç°çã§ã¯ãªãããFPAãšåå¿ããæäœ
ïŒç¬¬ïŒæäœïŒã«å¯ŸããŠç¹ç°çã§ããã第ïŒæäœã¯ã
第ïŒæäœãåŸãåç©ãšç°ãªãåç©ããæäœãåŸã
ã枬å®ãã¹ãæåã«å¯ŸããŠç¹ç°çã§ãªãåã®æ£åžž
åç©ã®ã¬ã³ãã°ãããªã³ã§ãæ¥çš®ããããšã«ãã€
ãŠè£œé ã§ããã第ïŒæäœã¯ãåäœäœæšèæåãã
ã³ç¬¬ïŒæäœã®è©Šè¬ã®åžéã«äœ¿çšãããã®ã«é¡äŒŒã
ãç·©è¡ç©è³ªäžã«ãåžéããŠãã¢ããã»ã€ã«ãããŠ
æé«ã®æ§èœãåŸãæ¿åºŠã«ããããšãã§ããã åé¢ãä¿é²ããããã«ãããªãšãã¬ã³ã°ãªã³ãŒ
ã«ãŸãã¯ä»ã®é©åœãªããªããŒãåå¿åªè³ªäžã«ã第
ïŒæäœæº¶æ¶²ã®æ·»å ã®åŸã«ããããã¯ãã®åã«ãã
ãŠãããå¥ã®è©Šè¬ãšããŠå ããããšã«ãããäŸçµŠ
ããããšãã§ããããã®ããªããŒã®ãã¹ãŠãŸãã¯
äž»èŠéšåãã第ïŒæäœè©Šè¬ãžåãã€ãŠæ··å ¥ããã
ãšã«ãããåå¿åªè³ªäžã«äŸçµŠããããšã奜ãŸã
ããããããŠãå žåçã«ã¯çŽïŒã15ééïŒ ã奜ãŸ
ããã¯çŽïŒã12ééïŒ ãããšãã°çŽïŒãïŒééïŒ
ã®ããªããŒã第ïŒæäœè©Šè¬äžã«å«ããŠãåå¿åªè³ª
äžã®ããªããŒã®æ¿åºŠãååã«ããŠãåäœäœæšèæ
åãŸãã¯æšèããªãæåãæãã第ïŒæ°Žæº¶æ¶²æäœ
ã®éã®å ç«æ²æ®¿åå¿ãå éããããšãã§ããã RIAãã¹ãã®ãããã³ãŒã«ã¯ãå åã®æ°ã«äŸå
ããŠå€åããããããããªãããäžè¬ã«ããã¹ã
è©Šè¬ã¯ãã¹ãŠå®€æž©ã«å¹³è¡¡åãã次ãã§åãã€ãŠæ±º
å®ããæ¿åºŠã®FPAãå«æããæšæºã®é©åœéãç³»
åã®ç®¡ã«å ããããšãã§ãããããŠè¡æŒ¿ã®è©Šæã
ä»ã®ç³»åã®ç®¡ã«å ããããšãã§ãã次ãã§æšè
FPAè©Šè¬ããã³FPAæäœè©Šè¬ãé çªã«ç®¡ã®ãã¹
ãŠã«å ããããšãã§ãã次ãã§ãããã®ç®¡ã枊çº
çæããããµãããããããŠå¹é€ããã第ïŒæäœ
ãåé¢ã«äœ¿çšãããšããããã次ã«ç®¡ãžå ããã
ãšãã§ãããå žåçã«ã¯ãæ¬çºæã«ããã°ã管ã®
å¹é€ã¯ç¬¬ïŒæäœã®æ·»å åŸäžå¿ èŠã§ãããã管ã¯å¿
èŠã«å¿ããŠå¹é€ããããšãã§ããã次ãã§ã管ã
枊çºçãããé å¿åé¢ããã管ããã«ã³ãããäž
æŸãå»æ£ã§ããã次ãã§ç®¡ãèšæ°ãããããŠæšæº
ããåŸãããå€ãçšããŠæšæºæ²ç·ãæ§æã§ããã
æšæºæ²ç·äžã«åŸãããå€ãããããããããšã«ã
ããæªç¥ã®è©Šæã«ã€ããŠå¹³åå€ã決å®ããããšã
ã§ãããæªç¥ã®FPAãå®éããããã«å®æœãã
èšç®ã¯ãæ®éã®æ¹æ³ã«åŸãããŒãã®FPAãå«æ
ãã管ã«ãããèšæ°ãã100ïŒ ã«èšå®ãããé¶
以äžã®çµæ¢ïŒclosingïŒããæšæºäžã®FPAãå¢å ã
ãã«ã€ããŠãèšæ°ïŒïŒ¢çµæ¢ãšããŠå®çŸ©ïŒã¯æžå°ã
ãããªããªããããã®èšæ°ã¯ãŒã管ã«ãããèšæ°
ã§å²ã€ãŠïŒ¢ïŒïŒ¢é¶ä»¥äžã®å€ãåŸãããã§ãããã
ã®ïŒ¢ïŒïŒ¢é¶ä»¥äžå€ããå察æ°ã°ã©ãçšçŽäžFPA
ã®æ¿åºŠã«å¯ŸããŠããããã§ãããïŒïŒ¢é¶ã®ããž
ãããïŒlogitïŒå€æããã³FPAæ¿åºŠãçšããŠã
æ²ç·ã«çŽç·ã«å€æã§ããã ããå Žåã«ãããŠãç¹ç°æäœãå«æããªãéç¹
ç°æ§çµåå¯Ÿç §ç·©è¡æ¶²ã圢æããããšãæãŸããã§
ãããããã®å¯Ÿç §ç·©è¡æ¶²ã䜿çšããŠãåå¿åªè³ªã
ãç¹å¥ã«åé¢ãããªãåäœäœæšèFPAã確èªã§
ããããããã®å Žåãçã®åãã¬ãŒãµãŒã¯ãéç¹
ç°èšæ°ããã¹ãŠã®è©Šæããæžããããšã«ãã€ãŠå®
éã§ããã æ¬çºæã®RIAæ³ã®å®æœã«ãããŠäœ¿çšããããã
å¿ èŠãªè©Šè¬ããã³ç©è³ªãå«æãããã±ãŒãžãã¹ã
ãããããæºåãããããã±ãŒãžã¯ïŒçš®é¡ä»¥äžã®
å¥ã ã®æåãæããããšãã§ããããã§åäœäœæš
èFPAè©Šè¬ãåèšFPAã«å¯ŸããŠç¹ç°çã§ããæ
äœè©Šè¬ãããã³æååºè©Šè¬ãæºåããããããã®
è©Šè¬ã®åã ãããã±ãŒãžã«ãããŠå¥ã ã®æåãšã
ãŠæºåããŠïŒæåã®ããã±ãŒãžã圢æããããã
ããã¯ãããã®è©Šè¬ã®ïŒçš®ãŸãã¯ãã以äžãçµã¿
åãããŠãïŒçš®é¡ããå°ãªãå¥ã ã®æåãæãã
ããã±ãŒãžã圢æã§ããããŸããã¹ãããã±ãŒãž
ã¯ãïŒçš®é¡ãŸãã¯ããããå°ãªãæåã«å ããŠã
è¿œå ã®æåãããšãã°ãæšæºè©Šæããã³å¯Ÿç §è©Šæ
ã調補ããããã®FPAè©Šè¬ãFPAã«å¯ŸããŠç¹ç°
çã§ãªããFPAæäœã«å¯ŸããŠç¹ç°çã§ãã第ïŒ
æäœè©Šè¬ãè¡æŒ¿ã®ååŠçè©Šè¬ããªãã³ã«ãã¹ãã
å®æœããè£ çœ®ãããšãã°è©Šè¬ã貯èµããã³ããã
ã¹ããå®æœããã€ããå Žåã«ãããŠè©Šè¬ãããšã
ã°ãå¯Ÿç §è©Šæããã³æšæºè©Šæã貯èµããå°ã³ãã
ãå«ãããšãã§ããããã®ããã±ãŒãžå šäœãåšå²
枩床ã§è²¯èµããã€éæ¬ãããããŠäœ¿çšè ã¯ããã
åãåã€ãæãå·èµåº«ã®æž©åºŠãããšãã°ãïŒâã
ïŒâã«ãããŠã䜿çšãããŸã§ã貯èµããããšãã§
ããã 以äžã®å®æœäŸã«ããæ¬çºæãããã«èª¬æãã
ããæ¬çºæã¯ãããã®å®æœäŸã«éå®ããããªãã å®æœäŸ ãã€ããªãããããã®ã©ãžãªã€ã ãã¢ãã»ã€
ã«ãããŠäœ¿çšããè©Šè¬ãã次ã®ããã«ããŠèª¿è£œã
ãïŒ ïŒ 0.1ïŒ ã®ãšãã¬ã³ãžã¢ãã³åé ¢é žããããªãŠ
ã ã0.2ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·ã¯ã
ããã·ã€ããã0.005ïŒ ã®ã¯ãã«ã¢ã³ããšãã³
ãŒã«ã0.584ïŒ ã®å¡©åãããªãŠã ãããã³0.005
ïŒ ã®FDïŒã€ãšããŒïŒïŒãå«æãã0.05ã¢ã«ã®
ããªã¹ç·©è¡æ¶²äžã«ãã»ãŒïŒããã°ã©ã ã®ïŒ®âã
ãã·ã«FPA â125ãå«æããããã€ããªã
ããããïŒFPAïŒïŒ©â125ã調補ããããã®
溶液ã®PHã¯ã8.40±0.05ã§ããããã®æº¶æ¶²ã¯10
ãã€ã¯ãCiããå°ãªãâ125ãå«æããã ïŒ 0.05ã¢ã«ã®ããªã¹ç·©è¡æ¶²ïŒ0.133WïŒïŒ¶ïŒ ã®
ãšãã¬ã³ãžã¢ãã³åé ¢é žããããªãŠã ã
0.30WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·ã¯
ãããã·ã€ããã0.005WïŒïŒ¶ïŒ ã®ã¯ãã«ã¢ã³
ããšãã³ãŒã«ã0.584WïŒïŒ¶ïŒ ã®å¡©åãããªãŠ
ã ããã³33KIUïŒïœã®ã¢ããããã³ãå«æã
ãïŒäžã§çŽç²ãªãã€ããªãããããæåã®é©
åœãªåžéãè¡ãããšã«ã€ãŠããã€ããªãããã
ãæšæºã調補ããããããã®æšæºã¯0.1ã
1.0ã2.0ã5.0ã10.0ã20.0ããã³40.0ããã°ã©
ã ïŒmlã«çããã ïŒ çŽç²ãªãã€ããªãããããæåãããªã¹ç·©
è¡ã¿ã³ãã¯æº¶æ¶²ïŒæšæºãšåäžïŒã«1.3ããã³8.0
ããã°ã©ã ïŒmlã®æŠç®æ¿åºŠã§å ããããšã«ãã€
ãŠããã€ããªãããããåè³ªå¯Ÿç §ç©è³ªã調補
ããã ïŒ æ¥åãããã€ããªãããããâãŠã·è¡æž ã¢
ã«ãã³å ç«åãåãã€ãŠæ¥çš®ãããŠãµã®ããæŸ
åºãããæè¡æž ããããã€ããªããããã第
ïŒæäœè©Šè¬ã調補ããããã®æè¡æž ã0.05ã¢ã«
ã®ããªã¹ç·©è¡æ¶²ïŒ0.10WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ãã
ã³ã0.04WïŒïŒ¶ïŒ ã®ã·ã¯ãããã·ã€ããã
0.005WïŒïŒ¶ïŒ ã®ã¯ãã«ã¢ã³ããšãã³ãŒã«ã
0.0035WïŒïŒ¶ïŒ ã®FDïŒãã«ãŒãã€ïŒïŒã
0.584WïŒïŒ¶ïŒ ã®å¡©åãããªãŠã ããã³
10USPKåäœïŒmlã®ãããªã³ãå«æããïŒã§
ïŒïŒ100ãã倧ããæ¯çã§åžéããã ïŒ é²è å€ãå«æãã0.1ã¢ã«ã®ãªã³é žãããªãŠ
ã ç·©è¡æ¶²äžã«6.5WïŒïŒ¶ïŒ ã®ååé6000ã7000
ã®ããªãšãã¬ã³ã°ã³ãŒã«ãå«æãããããªãšã
ã¬ã³ã°ãªã³ãŒã«ç¬¬ïŒæäœè©Šè¬ã調補ããã ïŒ 0.20WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·
ã¯ãããã·ã€ããã0.005ïŒ ã®ã¯ãã«ã¢ã³ããš
ãã³ãŒã«ããã³0.584ïŒ ã®å¡©åãããªãŠã ãå«
æãã0.05ã¢ã«ã®ãã¹ç·©è¡æ¶²ã«ã75mgïŒmlã®ã
ã³ããã€ããå ããããšã«ãã€ãŠããã³ããã€
ãã¹ã©ãªãŒã調補ããã ïŒ éç¹ç°çµåç·©è¡æ¶²ã¯ããããæãã€ããªãã
ãããæè¡æž ãå«æããªã以å€ã第ïŒæäœè©Š
è¬ãšåäžã§ããã ïŒ 4.0WïŒïŒ¶ïŒ ã®ãšãã¬ã³ãžã¢ãã³åé ¢é žã
1000KIUïŒmlã®ã¢ããããã³ïŒTrasylolïŒã
0.3ã0.6mgïŒmlã®ïŒ€âPheâProâArgCh2clã
ãã³0.9WïŒïŒ¶ïŒ ã®å¡©åãããªãŠã ãå«æãã
æååºå€æº¶æ¶²ã調補ããããã®æº¶æ¶²ã®PHã¯4.5
ã§ããã æååºè©Šæ管ã®èª¿è£œïŒ ïŒmlã®ææ°ããè¡æ¶²åé管äžã«0.5mlã®æååº
å€ããæ°å¯æ³šå°åšã«ããæ³šå ¥ããããããã®ç®¡ã¯
䜿çšãããŸã§ïŒâã§è²¯èµãã¹ãã§ããã è¡æ¶²è©Šæã®åéããã³èª¿è£œïŒ 20ã²ãŒãžã®äžæ¬ã®è©ŠæéãçšããŠãå®å šéèç©¿
åºã«ããè¡æ¶²ãåéãããéãéèã«ããå ¥ãã
åŸãæ¢è¡åž¯ãé€ããé©åœãªæååºå€ãå«æããæ
æ°ãã管äžã«ãïŒmlã®è¡æ¶²ãéããããã ããã«
åç«ãããããšã«ãããè¡æ¶²ãšæååºå€ãå®å šã«
æ··åããã è©Šæã¯ãåéåŸã§ããã ããã¿ããã«ã1000ã
1500Xgã§ïŒâãŸãã¯å®€æž©ã«ãããŠ20åéé å¿å
é¢ãã¹ãã§ãããè¡æŒ¿ã现èããåé¢ããã¢ãã»
ã€ãè¡ããŸã§ãâ20â以äžã®æž©åºŠã«ãããŠè²¯èµã
ãã è¡æŒ¿è©Šæã®åŠçœ®ïŒ 12Ã75ã®ã¬ã©ã¹ãããªããã¬ã³ãŸãã¯ããªãšã
ã¬ã³ã®ç®¡äžã«0.5mlïŒ500ÎŒïŒã®è¡æŒ¿ãåé ããã
枊ãçºçãããã€æäœ1200Xgã§10åéé å¿åé¢
ããã泚æããŠäžæŸãåžãåºããæž æµãªç®¡ãžç§»
ãããã®ãšããã³ããã€ãç²åã移ãããããã
ã¯åžãåºããªãããã«çšå¿ããã ã¢ãã»ã€æé ïŒ ïŒ èŠæ±ãããã¹ãæåãé å¿åé¢åšããåãåº
ãããããŠå®€æž©ïŒ20ã26âïŒã«å¹³è¡¡ã«ãããã ïŒ 0.00ã1.00ã2.00ã5.00ã10.00ã20.00ããã³
40.00ngïŒmlã®æšæºã®åã ã®200ãã€ã¯ããªãã
ã«ããäžç³»åã®ç®¡ã«å ããã200ÎŒã®æ£è ã®
åŠçããè©Šæããä»ã®ç³»åã®ç®¡ãžå ããã察å¿
ããå埩ããçµã®éç¹ç°çµåïŒNSBïŒç®¡ãã
200ÎŒã®0.00ngïŒmlã®æšæºã®æ·»å ã«ãã調補ã
ãã ïŒ 100ÎŒã®ãã€ããªããããã â125å
å¿æº¶æ¶²ããã¹ãŠã®ç®¡äžã«åé ããã ïŒ å管ãæ°ç§éãã ããã«æžŠçºçãããŠãå®å š
ãªæ··åã確ä¿ããã ïŒ 100ÎŒã®NSB緩衡液ãå ããNSB管ãé€å€
ããŠã100ÎŒã®ãã€ããªãããããæäœæº¶
液ããã¹ãŠã®ç®¡äžã«åé ããã ïŒ å管ãæ°ç§éãã ããã«æžŠçºçããŠãå®å šæ··
åã確ä¿ããã ïŒ ç®¡ããããããããŠå®€æž©ïŒ20ã26âïŒã§40ã
120åéå¹é€ããã ïŒ å·¥çšïŒã«ãããæäœæº¶æ¶²ã®åæ£ã«çšããã®ãš
åãæ·»å ã®é åºããã³é 次ã®æéãçšããŠã
PEGâ第ïŒæäœæº¶æ¶²ãããæ··åãããããŠ1.0
mlããã¹ãŠã®ç®¡ãžåé ãããæ°ç§éæ¿ãã枊çº
çããã ïŒ ãã¹ãŠã®ç®¡ã1200Xg以äžã«ãããŠå®€æž©ã§20
åéé å¿åé¢ããã 10 管ã®å 容ç©ããã«ã³ããããããŠæ¶²äœãå»æ£
ããããã¹ãŠã®ç®¡ãåžåçŽäžã«å°ããšãïŒåé
æ液ããã管ã®ãªãããçŽã¿ãªã«äžã«è»œããšã
ãšããšæã¡ã€ããŠãæ®ãã®æ¶²äœãåžåãããã 次ãã§ãå管ãæå°10000ã®èšæ°ã环ç©ããã
ãã«ååãªæéæŸå°æŽ»æ§ã«ã€ããŠèšæ°ãããããŠ
åæ¿åºŠã®æšæºããã³æ£è ã®è©Šæã®æ£å³ã®èšæ°ïŒå
ïŒcpmïŒã枬å®ãããããŠèšé²ãããåæšæºãæ£
è ãŸãã¯å¯Ÿç §ã®è¡æž ã®ç®¡ã®æ£å³ã®cpmããŒã
ngïŒmlã®æšæºç®¡ã®å¹³åã®æ£å³cpmã§å²ãããã
ãŠ100ãæãããåã¯ãFPAã®äžååšäžã®çµåé
ã«æ¯ã¹ãFPAã®ååšäžã®æäœãžçµåããFPA 
â125ã®æ¯çïŒïŒ¢ïŒB0ããŒã»ã³ãïŒãè¡šããã å察æ°ã°ã©ãçšçŽã®äžæ¬¡ã®è»žäžã«åæšæºã®äºé
å埩ãã¹ãå€ã®å¹³åã®ïŒ¢ïŒB0ããŒã»ã³ãããæš
æºã®æ¿åºŠïŒããã°ã©ã ïŒããªãªããã«ïŒã®é¢æ°ãš
ããŠãããããããããšã«ãããæšæºæ²ç·ãæ§æ
ãããåæ£è ã®è¡æž ããã³å¯Ÿç §è¡æž ã®äºéå埩ã
ã¹ãå€ã®å¹³åã®ïŒ¢ïŒB0ããŒã»ã³ãã決å®ããã
ããŠãã®æšæºæ²ç·ããã®æ£è ãŸãã¯å¯Ÿç §ã®è¡æž ã®
ïŒB0ããŒã»ã³ãå€ã«ã€ããŠã®FPAã®æ¿åºŠãã
決å®ãããFPAã®æ£å³ã®cpmå€ããã³ïŒ¢ïŒB0ã
ãŒã»ã³ãå€ãäžè¡šïŒã«èšèŒããã
FPAãšåŒã¶ïŒã®æ¿åºŠã枬å®ããã©ãžãªã€ã ãã¢
ãã»ã€RIAæ³ããã®ãããªæ¹æ³ã«ãããŠå©çšãã
æååºè©Šè¬ãããã³ãã®ãããªæ¹æ³ã«ãããŠå©çš
ããè©Šè¬ãå«æããããã±ãŒãžãã¹ããããã«é¢
ããã çŸåšãååºç³»äžã®çš®ã ã®ç©è³ªã®åææ³ã«ã€ããŠ
èå³ãå¢å€§ããŠããããããã®ç©è³ªã®ãã¡ã®ïŒçš®
ããªãã¡ãFPAã¯ãè¶ ååºèœåïŒhypercoagua
bilityïŒã®æ瀺ãäžããã§ããããååºç³»ã«ãã
ãäžç³»åã®äºè±¡ã¯ããã®ããã»ã¹ã«ãããæåã®
äºè±¡ãšããŠFPAã解æŸãããããã€ããªãã²ã³
ãžã®ããã³ãã³ã®äœçšãçããããã以äžã®äœçš
ã¯ãã€ããªãããããã解æŸãããŠãã€ããªã
ã¢ãããŒãçæãããã®ã¢ãããŒã¯ä»ã®é µçŽ ã®å©
ãããããŠéåããŠäžæº¶æ§ã®ã¯ããããšãªãã FPAã®å®éã«çŸåšçšããããŠããå®éšå®€ã®ã
ã¹ãã¯ãäžé©åã§ãããH.L.NoselãéçºããïŒ
ã€ã®ãã®ãããªRIAãã¹ãã¯ãMeasurement of
FPA in Human BloodïŒããã®è¡æ¶²äžã®FPAã®
枬å®ïŒãJJ.clin.Invest.54ïŒ43â53ïŒ1974ïŒããã³
Potential Use of FPA Measurements in the
Diagnosis and Measurement of ThrombosisïŒ
è¡æ çã®èšºæããã³æž¬å®ã«ãããFPA枬å®ã®å¯
èœæ§ãå èµãã䜿çšïŒãThrombosïŒDiathesïŒ
haemorrh.ïŒStuttgïŒ33ïŒ426ïŒ1975ïŒäžã«èšèŒã
ããŠããããããã®äž¡è ã®æç®ãåŒçšãã€ãŠãã
ã«å ããããã®ãã¹ãã¯ãæ£åžžã®åŸªç°ãããã€ã
ãªãã²ã³ã®çŽ200ngïŒçŽ0.09ïŒ ïŒã®çäœå 転åã«çž
åœããè¡æŒ¿ã®ïŒmlåœã2ngã®FPAããå°éã®æ€åº
ãã§ãããããããªãããè©Šæã®åéããã³åã
æ±ãã¯éåžžã«é倧ã§ããããããŠFPAã¬ãã«ã®
誀ãŸã€ãå¢å ããã°ãã°èŠãããã æ¬çºæã®ç®çã¯ã絶ããäžå®ããä¿¡é Œæ§ã®ãã
çµæãæäŸãããè¡æŒ¿äžã®FPAã®RIAæé ãæ
äŸããããšã§ããã æ¬çºæã«ããã°ããŸãè¡æ¶²ã®è©Šæãéããããš
ãããªããè¡æŒ¿äžã®FPAã®çäœå€æ¿åºŠã枬å®ã
ã競åRIAæ³ã®æ¹è¯ãæäŸãããã次ãã§ãåèš
è©Šæäžã®ããã³ãã³ãæå¶éã®ããã³ãã³æå¶å€
ã§æå¶ãããããŠè¡æŒ¿ãåèšè©Šæããåé¢ããã
次ã«ãåèšè¡æŒ¿ã®è©Šæããã©ãžãªã€ã ãã¢ãã»ã€
競åçµåæ¡ä»¶äžã«ãååãªéã®FPAã«å¯Ÿããæ
äœããã³æŸå°æŽ»æ§ã§æ°·èããFPAãšæ¥è§Šããã
ãã®åŸè¡æŒ¿çµåFPAãçµåããªãFPAããåé¢
ãããããŠæŸå°æŽ»æ§ã枬å®ãããæ¹è¯ã¯ãããã³
ãã³ãæå¶ããããã«ããçš®ã®æå¶å€ã䜿çšãã
ããšãå«ãã æ¬çºæã®ä»ã®å®æœæ æ§ã¯ãæå¶å€ã®ïŒçš®ããã¬
ãŒãå€ããã³æã¿ã³ãã¯å解å€ãå«æãããRIA
æ³ã«ãããŠäœ¿çšããæååºè©Šè¬ã«é¢ããã æ¬çºæã®ä»ã®é¢ã¯ããã®ãããªRIAæ³ã«ãããŠ
å©çšããè©Šè¬ãå«æããããã±ãŒãžãã¹ãããã
ã«é¢ããã æ¬çºæã«ãããŠäœ¿çšã§ããããã³ãã³æå¶å€
ã¯ãäœçšãéããããªãã¡ãããã³ãã³ãã»ãšã
ã©ç¬éçã«ãããšãã°ã10ç§ããçããæéã§æ
å¶ããè¡æŒ¿äžã§å®å®ã§ããããªãã¡ãFPAãã»
ãšãã©ãŸãã¯ãŸã€ãã圢æããããé·æéå®å®ã§
ãããããªãã¡ã䜿çšåéåžžã®è²¯èµå¯¿åœãæãã
ãããŠããã³ãã³ã®æ¬è³ªçã«äžå¯éçæå¶å€ã§ã
ãããã®ãããªæå¶å€ã®ïŒçš®ã¯ãâããšãã«ã¢
ã©ãã«ââãããªã«âââãïŒâïŒïŒâã¯ã
ãâïŒâã¯ã¢ããããã¿ã³âïŒâãªã³ïŒãïŒä»¥åŸã
âPheâProâArgCh2ClãšåŒã¶ïŒããã³ãã®é©
åœãªå¡©é¡ãããšãã°ãããã³ãã³ãæå¶ããã€å
è¿°ã®æ§è³ªãããªãã¡ãäœçšãéããè¡æŒ¿äžã§å®å®
ã§ãããªã©ã®æ§è³ªãæããå¡©é¡ã§ããã é©åœãªå¡©é¡ã¯ã匷ããŸãã¯åŒ±ãç¡æ©ãŸãã¯ææ©
ã®é žé¡ããèªå°ãããé žä»å å¡©é¡ãå å«ãããé©
åœãªç¡æ©é žã®äŸã¯ãããã²ã³å«æé žãããšãã°ã
å¡©é žãããåæ°ŽçŽ é žãŸãã¯èåæ°ŽçŽ é žïŒãªã³å«æ
é žãããšãã°ããªã³é žãäºãªã³é žã次äºãªã³é žïŒ
ã€ãªãŠå«æé žãããšãã°ãç¡«é žã次äºç¡«é žãŸãã¯
ããªç¡«é žïŒããã³ä»ã®é žãããšãã°ãç¡é žãŸãã¯
ãã³ã¬ã³é žã§ãããé©åœãªææ©é žã®äŸã¯ãã®é žã
é ¢é žãã¯ããé ¢é žãã¯ãšã³é žãä¹³é žãé ç³é žãªã©
ã§ããã é žä»å å¡©ã¯ãé©åœãªé žãå«æãã氎溶液äžã«é
é¢å¡©åºã溶ããããããŠãã®æº¶æ¶²ãèžçºããããš
ã«ããå¡©ãåé¢ããããšã«ãã€ãŠããããã¯éé¢
å¡©åºãšéžæããé žãšãææ©æº¶åªäžã§åå¿ãããã
ãšã«ãã€ãŠã補é ããåŸè ã®å Žåã«ãããŠãå¡©ã¯
çŽæ¥åé¢ãããããã¯ãã®æº¶æ¶²ã®æ¿çž®ã«ããåŸã
ããšãã§ãããïŒåœéãŸãã¯ãã以äžã®é žã䜿çš
ãããšããå€é žä»å å¡©ãåŸããããã®å Žåååäž
ã«ïŒåããå€ãå¡©åºæ§çªçŽ ååãååšãããïŒåœ
éã®é žã䜿çšãããšããäžé žä»å å¡©ãåŸãããã âPheâProâArgâCh2Clã®HFé žä»å å¡©ã
ãã³éé¢å¡©åºã¯ãæè¿ã®åè¡ç©ãKetherïŒ
Thrombosis Research 14ïŒ969â993ïŒ1979ïŒã«
èšèŒãããŠããæé ã«åŸã€ãŠè£œé ã§ããã è¿°ã¹ãããã«ãæ¬çºæã®æ¹æ³ã®ç¬¬ïŒå·¥çšã¯ãè¡
液詊æãéããåèšè©Šæäžã®ããã³ãã³ãæå¶ã
ãããŠåèšè©Šæããè¡æŒ¿ãåé¢ããããšãããª
ãã è¡æ¶²è©Šæã¯ãéåžžã®æ段ãããšãã°ã20ã²ãŒãž
ã®éãçšããéèç©¿åºã«ããéããããšãã§ã
ããäžè¬ã«ãïŒã10mlã®è¡æ¶²ãéããã è¡æ¶²è©Šæã¯ãã®åŸç¬éçã«ãŸãã¯çŽã¡ã«æå¶é
ã®åè¿°ã®æå¶å€ã®ïŒçš®ãšåãããŠãåèšè©Šæäžã®
ããã³ãã³ãæå¶ãããããšãã°ãæå¶éã¯ãå š
è¡ã®ïŒmlåœããçŽ0.001mgã1.0mgã奜ãŸããã¯çŽ
0.04ãçŽ0.6mgã§ãããæå©ã«ã¯ãæå¶å€ãšäžç·
ã«ããã¬ãŒãåéãããšãã°ãå šè¡ã®ïŒmlåœãçŽ
ïŒmgãïŒmgã奜ãŸããã¯çŽ3.5ã4.5mgã®ãã¬ãŒã
å€ãããšãã°ããšãã¬ã³ãžã¢ãã³åé ¢é žEDTA
ãŸãã¯ãšãã¬ã³ã°ãªã³ãŒã«ãã¹ïŒïŒ¢âã¢ãããšã
ã«ãšãŒãã«ïŒïŒ®ïŒïŒ®ïŒNâ²ïŒNâ²âåé ¢é žïŒEGTAïŒ
ãŸãã¯ãããã®å¡©ãåãããããšã«ãã€ãŠãçäœ
å€ã®ããã³ãã³ã®çºçã¯å®è³ªçã«ãŸãã¯å®å šã«æ
å¶ããããéåžžãFPAã®ã¿ã³ãã¯å解ãå®è³ªç
ã«æžå°ãããããããã¯é²æ¢ããããã®æã¿ã³ã
ã¯å解å€ãæã¿ã³ãã¯å解éããšãã°ãå šè¡ã®ïŒ
mlåœãçŽ50ã300KIUïŒã«ãªã¯ã¬ã€ã³æå¶å€åäœïŒ
奜ãŸããã¯çŽ90ã150KIUã®éã§å ããããã®ã
ããªæã¿ã³ãã¯å解å€ã®äŸã¯ãTrasylolïŒã¢
ããããã³ïŒã§ãããæå©ã«ã¯ãæ¬çºæã®ããã³
ãã³æå¶å€ã®ïŒçš®ãšäžç·ã«ãã¬ãŒãå€ããã³æã¿
ã³ãã¯å解å€ã䜿çšããããšã«ãã€ãŠãåéã®å
é¡ã¯ææã«è»œæžãããããŠå®€æž©ã«ãããŠæ°æéã
ããšãã°ãïŒãïŒæéãïŒâã«ãããŠæ°æ¥éãã
ãšãã°ãïŒãïŒæ¥éããããŠâ20âã«ãããŠæ°ã«
æéãããšãã°ïŒãïŒã«æéãå®å®ãªè¡æŒ¿è©Šæã
åŸãããã ãã¹ãŠã®ïŒçš®é¡ã®ç©è³ªã¯ãæå©ã«ã¯ã氎溶液ã
ããšãã°ãå¡©åãããªãŠã ãŸãã¯ç·©è¡å€ã®æ°Žæº¶äž
ã§ã䟿å©ã«çµåããŠæååºè©Šè¬ã圢æã§ãããæ
ååºè©Šè¬ã¯ååãªéã®æå¶å€ããã¬ãŒãå€ããã³
æã¿ã³ãã¯å解å€ãå«æããããã«ããåã ã¯ã
æååºè©Šè¬ãè¡æ¶²ã«å ãããšãããã®æå³ããæ©
èœãçºæ®ãããéåžžãæ°Žæ§æååºè©Šè¬ã®åïŒmläž
ã«ãçŽ0.1mgãçŽïŒmgã奜ãŸããã¯çŽ0.4ãçŽ0.6mg
ã®æå¶å€ãååšããçŽ20mgãçŽ60mgã奜ãŸããã¯
çŽ35mgçŽ45mgã®ãã¬ãŒãå€ãååšãããããŠçŽ
500ãçŽ3000KIUïŒmgã奜ãŸããã¯çŽ900ãçŽ
1500KIUïŒmlã®æã¿ã³ãã¯è³ªå€ãååšãããè©Š
è¬ã¯æååºéã§äœ¿çšãããšãã°æ°Žæ§è©Šè¬ã¯ãå šè¡
ïŒmlåœããçŽ0.05ãçŽïŒmlã奜ãŸããã¯çŽ0.1ã
çŽ0.2mlã®éã§äœ¿çšãããè©Šè¬ã®PHã¯ãäžè¬ã«çŽ
ïŒãïŒã§ããã 次ã«ãè¡æŒ¿ãåžžæž©ã«ãããŠé å¿åé¢ããããšã«
ãããããšãã°ã1000ã15000Xgã«ãããŠãåå
æéãããšãã°ã20åéïŒâãŸãã¯å®€æž©ã«ãããŠ
é å¿åé¢ããããšã«ããã奜ãŸããã¯ãããã¯å
éåŸã§ããã ãéããã«å®æœãããåé¢ããè¡æŒ¿
ã¯é©åœãªæž©åºŠãããšãã°ã20â以äžã§ãæ¬çºæã«
åŸãRIAã¢ãã»ã€ã€ã«ãããŠäœ¿çšãããŸã§ã貯èµ
ããã RIAæé ã«ãããŠè¡æŒ¿ã䜿çšããåã«ãéåžžã
ããååŠçããŠæ©ããåå¿æ§ã®ãã€ããªãã²ã³ã
ãã³ãã€ããªã³ïŒãã€ããªãã²ã³ïŒæçãè¡æŒ¿ã
ãé€å»ããªããŠã¯ãªããªããããã¯åžžæ³ã«ãã
ãŠãããšãã°ãè¡æŒ¿ãã¢ã«ã³ãŒã«ã§æ²æ®¿ãããã
ãŠæ¶²ãéæããããšã«ãã€ãŠããããã¯ãã³ã
ãã€ããŸãã¯ä»ã®åæ§ãªäœçšç©è³ªãè¡æŒ¿ã«ååãª
éã§æ·»å ããŠåŠšå®³ç©è³ªãè¡æŒ¿ããé€å»ããããšã«
ãã€ãŠãå®æœã§ãããéåžžããã³ããã€ãã®ã¹ã©
ãªãŒãè¡æŒ¿æ··åç©ãžå ããã次ãã§ãè¡æŒ¿ãæ··å
ããæå°1200Xgã«ãããŠååãªæéãããšãã°ã
20åéé å¿åé¢ãããäžæŸãåãåºãããããŠã¢
ãã»ã€æ³ã«äœ¿çšããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒå·¥çšã¯ãRIAã¢ãã»ã€ã
RIA競çµåæ¡ä»¶äžã§åžžæ³ã«ãããŠãããšãã°ãå
è¿°ã®NOSSELåè¡ç©ã«èšèŒãããããã«ããŠã
å®æœããããšãããªããåºæ¬çã«ã¯ãããã¯åå
ãªéã®FPAã«å¯Ÿããæäœããã³æŸå°æŽ»æ§ã§æšè
ããFPAãè¡æŒ¿è©Šæã«å ãããã®åŸæäœçµåã
ãFPAãçµåããªãFPAããåé¢ãããããŠæŸ
å°æŽ»æ§ã枬å®ããããšãããªãã FPAæäœãšåå¿ããæŸå°æŽ»æ§ã§æšèããFPA
ã䜿çšã§ããã䟿å©ã«ã¯ãæŸå°æŽ»æ§ã§æšèããã
ã¹ã¢ããããã·ã«ãŒFPAé¯äœã䜿çšã§ãããã
ãã¯ãããšãã°ãâ125ãŸãã¯ä»ã®æŸå°æ§åäœ
äœã§ã¯ãã©ãã³ïŒŽæ³ãçšããŠæšèããããšãã§ã
ãããã®é¯äœã補é ãã詳现ãªæé ã¯ãåè¿°ã®
NOSSELåè¡ç©ã«ãããŠèŠãã ãããšãã§ããã äžè¬ã«ãFPAãâ125ãŸãã¯ä»ã®æŸå°æ§åäœ
äœã§çŽ800ãçŽ1600ãã€ã¯ãããŠãªãŒïŒãã€ã¯ã
ã°ã©ã ã®æ¯æŽ»æ§ã«æšèããããã®åäœäœæšè
FPAããã®åéã§ç¥ãããŠããããã«åžéããŠã
åå¿åªè³ªäžã§æäœãšçæ³çãªå ç«æž¬å®äŒåãè¡ã
ããšãã§ããåäœäœæšèè©Šè¬ããã³æé©ãªã¢ãã»
ã€æ床ãåŸãããšãã§ããããã®åžéã¯ãPHçŽïŒ
ã10ã®é©åœãªæ°Žæ§ç·©è¡æ¶²ãçšããŠå®æœã§ãããã
ã®åžéã«çšããããšãã§ããé©åœãªç·©è¡æ¶²ã¯ãã
ãªã¹ïŒTrisïŒãåæ¥çã«å ¥æã§ãããããªã¹ïŒã
ããããã·ã¡ãã«ã«ïŒã¢ããã¡ã¿ã³ãå«æããæ°Ž
溶液ïŒãã«ãã¿ãŒã«ãåæ¥çã«å ¥æã§ããïŒïŒïŒ
âãžãšãã«ãã«ããã«é žã®æ°Žæº¶æ¶²ããã³ä»ã®ãã
ç¥ãããç·©è¡æ¶²ã§ãããåžé床ã¯ãçšããå Žåã
åæã®æ¯æŽ»æ§ãããã³ææã®æé©ãªèšæ°ããã³ã¢
ãã»ã€ã®æ床ãå®çŸããããã«èŠããææã®åŽ©
å£ïŒåïŒDPMïŒã«äŸåãããã è¡æŒ¿ã®æªç¥ã®è©ŠæãæŸå°æŽ»æ§ã§æšèããFPA
è©Šè¬ãšæ··åããåŸãæäœãããšãã°ãFPAãšå
ç«åå¿ãããæäœãšæŸå°æŽ»æ§FPAãå«æããæ
äœæº¶æ¶²ãæ··åç©ãžå ãããæäœã¯FPAããã³æŸ
å°æŽ»æ§FPAã«å¯Ÿããç¹ç°æ§ãæãããããããŠã
æäœã®æå®éã«ãã€ãŠçµåãããæŸå°æŽ»æ§FPA
ã®éã¯æªç¥ã®è¡æŒ¿è©Šè¬ããã®æšèããªãFPAã®
ååšã§æžå°ãããããŠãã®å¹æã¯æšèããªã
FPAã®æ¿åºŠã«çŽæ¥é¢ä¿ããã ãã®åéã§æ¢ç¥ã®æ¹æ³ããFPAããã³æšè
FPAãšåå¿ãããæäœãåŸãããã«ããããšã
ã§ãããããšãã°ãæäœã¯å®¿äž»åç©ãããšãã°ã
ãŠãµã®ãæ¥çš®ããããšã«ãã€ãŠè£œé ããããšãã§
ãããæ¥çš®åŸãããæéãçµéããããã®é宿䞻
ã¯æäœãçæãã次ãã§æè¡æž ããã®åç©ããæŸ
åºãããŠæäœãåŸãããã®æäœããæŸå°æŽ»æ§ã§æš
èããFPAã®åžéã«äœ¿çšãããã®ã«é¡äŒŒããç·©
è¡ç©è³ªäžã«ãåžéããŠã¢ãã»ã€ã«ãããŠæé«ã®æ§
èœãåŸãæ¿åºŠã«ããŠç¬¬ïŒæäœè©Šè¬ã圢æãããã
ãšãã°ããã¬ãŒãµãŒéã®æŸå°æŽ»æ§FPAïŒ0.01ã
0.09CiïŒã®20ã80ïŒ ã奜ãŸããã¯30ã70ïŒ ãçµå
ããçšåºŠã«æè¡æž ãåžéããããšã奜ãŸãããæ
äœãè¡æŒ¿ã®æ··åç©ãžãã€ããå ãããšãåŸããã
æ··åç©ããæäœçµåFPAããã³çµåããªãFPA
ã®å®è³ªçãªå¹³è¡¡ãçæãã枩床ã«ãããŠååãªæ
éå¹é€ãããå¹é€æéäžãåžéãããæè¡æž äžã®
æäœã¯æŸå°æŽ»æ§FPAããã³FPAãšå ç«é¯äœã圢
æãããæ¬çºæã®å®æœã«ãããŠãå¹é€å·¥çšã¯çŽ15
ã37âã奜ãŸããã¯20ã30âã®æž©åºŠã§ã»ãŒ40ã
120åéã奜ãŸããã¯40åéå®æœããããšã奜ãŸ
ããããã®åŸæäœã«ããFPAã®çµåã¯å®è³ªçå¹³
è¡¡ã«å°éããããšãããã€ãã å¹é€å·¥çšãå®çµãããšããçµåããªãFPAã
æäœçµåFPAããåé¢ããã åé¢ã¯ãæšçããããã¯ã€ãªã³äº€ææš¹èããæ¬
質çã«æãèã®èãã¹ããªãããå å«ããåžžæ³ã«
ãã䟿å©ã«å®æœããããä»ã®åé¢æè¡ã¯ç¬¬ïŒæäœ
ã䜿çšããæè¡ã§ããããã®ç¬¬ïŒæäœã¯FPAã«
察ããŠç¹ç°çã§ã¯ãªãããFPAãšåå¿ããæäœ
ïŒç¬¬ïŒæäœïŒã«å¯ŸããŠç¹ç°çã§ããã第ïŒæäœã¯ã
第ïŒæäœãåŸãåç©ãšç°ãªãåç©ããæäœãåŸã
ã枬å®ãã¹ãæåã«å¯ŸããŠç¹ç°çã§ãªãåã®æ£åžž
åç©ã®ã¬ã³ãã°ãããªã³ã§ãæ¥çš®ããããšã«ãã€
ãŠè£œé ã§ããã第ïŒæäœã¯ãåäœäœæšèæåãã
ã³ç¬¬ïŒæäœã®è©Šè¬ã®åžéã«äœ¿çšãããã®ã«é¡äŒŒã
ãç·©è¡ç©è³ªäžã«ãåžéããŠãã¢ããã»ã€ã«ãããŠ
æé«ã®æ§èœãåŸãæ¿åºŠã«ããããšãã§ããã åé¢ãä¿é²ããããã«ãããªãšãã¬ã³ã°ãªã³ãŒ
ã«ãŸãã¯ä»ã®é©åœãªããªããŒãåå¿åªè³ªäžã«ã第
ïŒæäœæº¶æ¶²ã®æ·»å ã®åŸã«ããããã¯ãã®åã«ãã
ãŠãããå¥ã®è©Šè¬ãšããŠå ããããšã«ãããäŸçµŠ
ããããšãã§ããããã®ããªããŒã®ãã¹ãŠãŸãã¯
äž»èŠéšåãã第ïŒæäœè©Šè¬ãžåãã€ãŠæ··å ¥ããã
ãšã«ãããåå¿åªè³ªäžã«äŸçµŠããããšã奜ãŸã
ããããããŠãå žåçã«ã¯çŽïŒã15ééïŒ ã奜ãŸ
ããã¯çŽïŒã12ééïŒ ãããšãã°çŽïŒãïŒééïŒ
ã®ããªããŒã第ïŒæäœè©Šè¬äžã«å«ããŠãåå¿åªè³ª
äžã®ããªããŒã®æ¿åºŠãååã«ããŠãåäœäœæšèæ
åãŸãã¯æšèããªãæåãæãã第ïŒæ°Žæº¶æ¶²æäœ
ã®éã®å ç«æ²æ®¿åå¿ãå éããããšãã§ããã RIAãã¹ãã®ãããã³ãŒã«ã¯ãå åã®æ°ã«äŸå
ããŠå€åããããããããªãããäžè¬ã«ããã¹ã
è©Šè¬ã¯ãã¹ãŠå®€æž©ã«å¹³è¡¡åãã次ãã§åãã€ãŠæ±º
å®ããæ¿åºŠã®FPAãå«æããæšæºã®é©åœéãç³»
åã®ç®¡ã«å ããããšãã§ãããããŠè¡æŒ¿ã®è©Šæã
ä»ã®ç³»åã®ç®¡ã«å ããããšãã§ãã次ãã§æšè
FPAè©Šè¬ããã³FPAæäœè©Šè¬ãé çªã«ç®¡ã®ãã¹
ãŠã«å ããããšãã§ãã次ãã§ãããã®ç®¡ã枊çº
çæããããµãããããããŠå¹é€ããã第ïŒæäœ
ãåé¢ã«äœ¿çšãããšããããã次ã«ç®¡ãžå ããã
ãšãã§ãããå žåçã«ã¯ãæ¬çºæã«ããã°ã管ã®
å¹é€ã¯ç¬¬ïŒæäœã®æ·»å åŸäžå¿ èŠã§ãããã管ã¯å¿
èŠã«å¿ããŠå¹é€ããããšãã§ããã次ãã§ã管ã
枊çºçãããé å¿åé¢ããã管ããã«ã³ãããäž
æŸãå»æ£ã§ããã次ãã§ç®¡ãèšæ°ãããããŠæšæº
ããåŸãããå€ãçšããŠæšæºæ²ç·ãæ§æã§ããã
æšæºæ²ç·äžã«åŸãããå€ãããããããããšã«ã
ããæªç¥ã®è©Šæã«ã€ããŠå¹³åå€ã決å®ããããšã
ã§ãããæªç¥ã®FPAãå®éããããã«å®æœãã
èšç®ã¯ãæ®éã®æ¹æ³ã«åŸãããŒãã®FPAãå«æ
ãã管ã«ãããèšæ°ãã100ïŒ ã«èšå®ãããé¶
以äžã®çµæ¢ïŒclosingïŒããæšæºäžã®FPAãå¢å ã
ãã«ã€ããŠãèšæ°ïŒïŒ¢çµæ¢ãšããŠå®çŸ©ïŒã¯æžå°ã
ãããªããªããããã®èšæ°ã¯ãŒã管ã«ãããèšæ°
ã§å²ã€ãŠïŒ¢ïŒïŒ¢é¶ä»¥äžã®å€ãåŸãããã§ãããã
ã®ïŒ¢ïŒïŒ¢é¶ä»¥äžå€ããå察æ°ã°ã©ãçšçŽäžFPA
ã®æ¿åºŠã«å¯ŸããŠããããã§ãããïŒïŒ¢é¶ã®ããž
ãããïŒlogitïŒå€æããã³FPAæ¿åºŠãçšããŠã
æ²ç·ã«çŽç·ã«å€æã§ããã ããå Žåã«ãããŠãç¹ç°æäœãå«æããªãéç¹
ç°æ§çµåå¯Ÿç §ç·©è¡æ¶²ã圢æããããšãæãŸããã§
ãããããã®å¯Ÿç §ç·©è¡æ¶²ã䜿çšããŠãåå¿åªè³ªã
ãç¹å¥ã«åé¢ãããªãåäœäœæšèFPAã確èªã§
ããããããã®å Žåãçã®åãã¬ãŒãµãŒã¯ãéç¹
ç°èšæ°ããã¹ãŠã®è©Šæããæžããããšã«ãã€ãŠå®
éã§ããã æ¬çºæã®RIAæ³ã®å®æœã«ãããŠäœ¿çšããããã
å¿ èŠãªè©Šè¬ããã³ç©è³ªãå«æãããã±ãŒãžãã¹ã
ãããããæºåãããããã±ãŒãžã¯ïŒçš®é¡ä»¥äžã®
å¥ã ã®æåãæããããšãã§ããããã§åäœäœæš
èFPAè©Šè¬ãåèšFPAã«å¯ŸããŠç¹ç°çã§ããæ
äœè©Šè¬ãããã³æååºè©Šè¬ãæºåããããããã®
è©Šè¬ã®åã ãããã±ãŒãžã«ãããŠå¥ã ã®æåãšã
ãŠæºåããŠïŒæåã®ããã±ãŒãžã圢æããããã
ããã¯ãããã®è©Šè¬ã®ïŒçš®ãŸãã¯ãã以äžãçµã¿
åãããŠãïŒçš®é¡ããå°ãªãå¥ã ã®æåãæãã
ããã±ãŒãžã圢æã§ããããŸããã¹ãããã±ãŒãž
ã¯ãïŒçš®é¡ãŸãã¯ããããå°ãªãæåã«å ããŠã
è¿œå ã®æåãããšãã°ãæšæºè©Šæããã³å¯Ÿç §è©Šæ
ã調補ããããã®FPAè©Šè¬ãFPAã«å¯ŸããŠç¹ç°
çã§ãªããFPAæäœã«å¯ŸããŠç¹ç°çã§ãã第ïŒ
æäœè©Šè¬ãè¡æŒ¿ã®ååŠçè©Šè¬ããªãã³ã«ãã¹ãã
å®æœããè£ çœ®ãããšãã°è©Šè¬ã貯èµããã³ããã
ã¹ããå®æœããã€ããå Žåã«ãããŠè©Šè¬ãããšã
ã°ãå¯Ÿç §è©Šæããã³æšæºè©Šæã貯èµããå°ã³ãã
ãå«ãããšãã§ããããã®ããã±ãŒãžå šäœãåšå²
枩床ã§è²¯èµããã€éæ¬ãããããŠäœ¿çšè ã¯ããã
åãåã€ãæãå·èµåº«ã®æž©åºŠãããšãã°ãïŒâã
ïŒâã«ãããŠã䜿çšãããŸã§ã貯èµããããšãã§
ããã 以äžã®å®æœäŸã«ããæ¬çºæãããã«èª¬æãã
ããæ¬çºæã¯ãããã®å®æœäŸã«éå®ããããªãã å®æœäŸ ãã€ããªãããããã®ã©ãžãªã€ã ãã¢ãã»ã€
ã«ãããŠäœ¿çšããè©Šè¬ãã次ã®ããã«ããŠèª¿è£œã
ãïŒ ïŒ 0.1ïŒ ã®ãšãã¬ã³ãžã¢ãã³åé ¢é žããããªãŠ
ã ã0.2ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·ã¯ã
ããã·ã€ããã0.005ïŒ ã®ã¯ãã«ã¢ã³ããšãã³
ãŒã«ã0.584ïŒ ã®å¡©åãããªãŠã ãããã³0.005
ïŒ ã®FDïŒã€ãšããŒïŒïŒãå«æãã0.05ã¢ã«ã®
ããªã¹ç·©è¡æ¶²äžã«ãã»ãŒïŒããã°ã©ã ã®ïŒ®âã
ãã·ã«FPA â125ãå«æããããã€ããªã
ããããïŒFPAïŒïŒ©â125ã調補ããããã®
溶液ã®PHã¯ã8.40±0.05ã§ããããã®æº¶æ¶²ã¯10
ãã€ã¯ãCiããå°ãªãâ125ãå«æããã ïŒ 0.05ã¢ã«ã®ããªã¹ç·©è¡æ¶²ïŒ0.133WïŒïŒ¶ïŒ ã®
ãšãã¬ã³ãžã¢ãã³åé ¢é žããããªãŠã ã
0.30WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·ã¯
ãããã·ã€ããã0.005WïŒïŒ¶ïŒ ã®ã¯ãã«ã¢ã³
ããšãã³ãŒã«ã0.584WïŒïŒ¶ïŒ ã®å¡©åãããªãŠ
ã ããã³33KIUïŒïœã®ã¢ããããã³ãå«æã
ãïŒäžã§çŽç²ãªãã€ããªãããããæåã®é©
åœãªåžéãè¡ãããšã«ã€ãŠããã€ããªãããã
ãæšæºã調補ããããããã®æšæºã¯0.1ã
1.0ã2.0ã5.0ã10.0ã20.0ããã³40.0ããã°ã©
ã ïŒmlã«çããã ïŒ çŽç²ãªãã€ããªãããããæåãããªã¹ç·©
è¡ã¿ã³ãã¯æº¶æ¶²ïŒæšæºãšåäžïŒã«1.3ããã³8.0
ããã°ã©ã ïŒmlã®æŠç®æ¿åºŠã§å ããããšã«ãã€
ãŠããã€ããªãããããåè³ªå¯Ÿç §ç©è³ªã調補
ããã ïŒ æ¥åãããã€ããªãããããâãŠã·è¡æž ã¢
ã«ãã³å ç«åãåãã€ãŠæ¥çš®ãããŠãµã®ããæŸ
åºãããæè¡æž ããããã€ããªããããã第
ïŒæäœè©Šè¬ã調補ããããã®æè¡æž ã0.05ã¢ã«
ã®ããªã¹ç·©è¡æ¶²ïŒ0.10WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ãã
ã³ã0.04WïŒïŒ¶ïŒ ã®ã·ã¯ãããã·ã€ããã
0.005WïŒïŒ¶ïŒ ã®ã¯ãã«ã¢ã³ããšãã³ãŒã«ã
0.0035WïŒïŒ¶ïŒ ã®FDïŒãã«ãŒãã€ïŒïŒã
0.584WïŒïŒ¶ïŒ ã®å¡©åãããªãŠã ããã³
10USPKåäœïŒmlã®ãããªã³ãå«æããïŒã§
ïŒïŒ100ãã倧ããæ¯çã§åžéããã ïŒ é²è å€ãå«æãã0.1ã¢ã«ã®ãªã³é žãããªãŠ
ã ç·©è¡æ¶²äžã«6.5WïŒïŒ¶ïŒ ã®ååé6000ã7000
ã®ããªãšãã¬ã³ã°ã³ãŒã«ãå«æãããããªãšã
ã¬ã³ã°ãªã³ãŒã«ç¬¬ïŒæäœè©Šè¬ã調補ããã ïŒ 0.20WïŒïŒ¶ïŒ ã®ãŠãã¢ã«ããã³ã0.04ïŒ ã®ã·
ã¯ãããã·ã€ããã0.005ïŒ ã®ã¯ãã«ã¢ã³ããš
ãã³ãŒã«ããã³0.584ïŒ ã®å¡©åãããªãŠã ãå«
æãã0.05ã¢ã«ã®ãã¹ç·©è¡æ¶²ã«ã75mgïŒmlã®ã
ã³ããã€ããå ããããšã«ãã€ãŠããã³ããã€
ãã¹ã©ãªãŒã調補ããã ïŒ éç¹ç°çµåç·©è¡æ¶²ã¯ããããæãã€ããªãã
ãããæè¡æž ãå«æããªã以å€ã第ïŒæäœè©Š
è¬ãšåäžã§ããã ïŒ 4.0WïŒïŒ¶ïŒ ã®ãšãã¬ã³ãžã¢ãã³åé ¢é žã
1000KIUïŒmlã®ã¢ããããã³ïŒTrasylolïŒã
0.3ã0.6mgïŒmlã®ïŒ€âPheâProâArgCh2clã
ãã³0.9WïŒïŒ¶ïŒ ã®å¡©åãããªãŠã ãå«æãã
æååºå€æº¶æ¶²ã調補ããããã®æº¶æ¶²ã®PHã¯4.5
ã§ããã æååºè©Šæ管ã®èª¿è£œïŒ ïŒmlã®ææ°ããè¡æ¶²åé管äžã«0.5mlã®æååº
å€ããæ°å¯æ³šå°åšã«ããæ³šå ¥ããããããã®ç®¡ã¯
䜿çšãããŸã§ïŒâã§è²¯èµãã¹ãã§ããã è¡æ¶²è©Šæã®åéããã³èª¿è£œïŒ 20ã²ãŒãžã®äžæ¬ã®è©ŠæéãçšããŠãå®å šéèç©¿
åºã«ããè¡æ¶²ãåéãããéãéèã«ããå ¥ãã
åŸãæ¢è¡åž¯ãé€ããé©åœãªæååºå€ãå«æããæ
æ°ãã管äžã«ãïŒmlã®è¡æ¶²ãéããããã ããã«
åç«ãããããšã«ãããè¡æ¶²ãšæååºå€ãå®å šã«
æ··åããã è©Šæã¯ãåéåŸã§ããã ããã¿ããã«ã1000ã
1500Xgã§ïŒâãŸãã¯å®€æž©ã«ãããŠ20åéé å¿å
é¢ãã¹ãã§ãããè¡æŒ¿ã现èããåé¢ããã¢ãã»
ã€ãè¡ããŸã§ãâ20â以äžã®æž©åºŠã«ãããŠè²¯èµã
ãã è¡æŒ¿è©Šæã®åŠçœ®ïŒ 12Ã75ã®ã¬ã©ã¹ãããªããã¬ã³ãŸãã¯ããªãšã
ã¬ã³ã®ç®¡äžã«0.5mlïŒ500ÎŒïŒã®è¡æŒ¿ãåé ããã
枊ãçºçãããã€æäœ1200Xgã§10åéé å¿åé¢
ããã泚æããŠäžæŸãåžãåºããæž æµãªç®¡ãžç§»
ãããã®ãšããã³ããã€ãç²åã移ãããããã
ã¯åžãåºããªãããã«çšå¿ããã ã¢ãã»ã€æé ïŒ ïŒ èŠæ±ãããã¹ãæåãé å¿åé¢åšããåãåº
ãããããŠå®€æž©ïŒ20ã26âïŒã«å¹³è¡¡ã«ãããã ïŒ 0.00ã1.00ã2.00ã5.00ã10.00ã20.00ããã³
40.00ngïŒmlã®æšæºã®åã ã®200ãã€ã¯ããªãã
ã«ããäžç³»åã®ç®¡ã«å ããã200ÎŒã®æ£è ã®
åŠçããè©Šæããä»ã®ç³»åã®ç®¡ãžå ããã察å¿
ããå埩ããçµã®éç¹ç°çµåïŒNSBïŒç®¡ãã
200ÎŒã®0.00ngïŒmlã®æšæºã®æ·»å ã«ãã調補ã
ãã ïŒ 100ÎŒã®ãã€ããªããããã â125å
å¿æº¶æ¶²ããã¹ãŠã®ç®¡äžã«åé ããã ïŒ å管ãæ°ç§éãã ããã«æžŠçºçãããŠãå®å š
ãªæ··åã確ä¿ããã ïŒ 100ÎŒã®NSB緩衡液ãå ããNSB管ãé€å€
ããŠã100ÎŒã®ãã€ããªãããããæäœæº¶
液ããã¹ãŠã®ç®¡äžã«åé ããã ïŒ å管ãæ°ç§éãã ããã«æžŠçºçããŠãå®å šæ··
åã確ä¿ããã ïŒ ç®¡ããããããããŠå®€æž©ïŒ20ã26âïŒã§40ã
120åéå¹é€ããã ïŒ å·¥çšïŒã«ãããæäœæº¶æ¶²ã®åæ£ã«çšããã®ãš
åãæ·»å ã®é åºããã³é 次ã®æéãçšããŠã
PEGâ第ïŒæäœæº¶æ¶²ãããæ··åãããããŠ1.0
mlããã¹ãŠã®ç®¡ãžåé ãããæ°ç§éæ¿ãã枊çº
çããã ïŒ ãã¹ãŠã®ç®¡ã1200Xg以äžã«ãããŠå®€æž©ã§20
åéé å¿åé¢ããã 10 管ã®å 容ç©ããã«ã³ããããããŠæ¶²äœãå»æ£
ããããã¹ãŠã®ç®¡ãåžåçŽäžã«å°ããšãïŒåé
æ液ããã管ã®ãªãããçŽã¿ãªã«äžã«è»œããšã
ãšããšæã¡ã€ããŠãæ®ãã®æ¶²äœãåžåãããã 次ãã§ãå管ãæå°10000ã®èšæ°ã环ç©ããã
ãã«ååãªæéæŸå°æŽ»æ§ã«ã€ããŠèšæ°ãããããŠ
åæ¿åºŠã®æšæºããã³æ£è ã®è©Šæã®æ£å³ã®èšæ°ïŒå
ïŒcpmïŒã枬å®ãããããŠèšé²ãããåæšæºãæ£
è ãŸãã¯å¯Ÿç §ã®è¡æž ã®ç®¡ã®æ£å³ã®cpmããŒã
ngïŒmlã®æšæºç®¡ã®å¹³åã®æ£å³cpmã§å²ãããã
ãŠ100ãæãããåã¯ãFPAã®äžååšäžã®çµåé
ã«æ¯ã¹ãFPAã®ååšäžã®æäœãžçµåããFPA 
â125ã®æ¯çïŒïŒ¢ïŒB0ããŒã»ã³ãïŒãè¡šããã å察æ°ã°ã©ãçšçŽã®äžæ¬¡ã®è»žäžã«åæšæºã®äºé
å埩ãã¹ãå€ã®å¹³åã®ïŒ¢ïŒB0ããŒã»ã³ãããæš
æºã®æ¿åºŠïŒããã°ã©ã ïŒããªãªããã«ïŒã®é¢æ°ãš
ããŠãããããããããšã«ãããæšæºæ²ç·ãæ§æ
ãããåæ£è ã®è¡æž ããã³å¯Ÿç §è¡æž ã®äºéå埩ã
ã¹ãå€ã®å¹³åã®ïŒ¢ïŒB0ããŒã»ã³ãã決å®ããã
ããŠãã®æšæºæ²ç·ããã®æ£è ãŸãã¯å¯Ÿç §ã®è¡æž ã®
ïŒB0ããŒã»ã³ãå€ã«ã€ããŠã®FPAã®æ¿åºŠãã
決å®ãããFPAã®æ£å³ã®cpmå€ããã³ïŒ¢ïŒB0ã
ãŒã»ã³ãå€ãäžè¡šïŒã«èšèŒããã
ãè¡šã
ãè¡šã
å®æœäŸ
幎什25ã60æã®35人ã®æ£åžžãªè¢«éšè
ã«ã€ããŠã®
äºåããŒã¿ã¯ãè¡æŒ¿ã®ïŒmlåœã0.3ã1.7ããã°ã©
ã ã®å€ãäžããã å€æ°ã®ã¢ãã»ã€ã«ã€ããŠå®éšå ããã³å®éšéã«
ãããŠãå€åçã¯10ïŒ ããå°ã§ããããšã瀺ãã
ãã0.1ããã°ã©ã ïŒããªãªããã«çšåºŠã«äœãå€
ãã0.0ããã°ã©ã ïŒããªãªããã«ã®æšæºãšåºå¥
ã§ããã çš®ã ã®éã®çŽç²ãªãã€ããªããããããå ã
ãïŒçš®é¡ã®å¥ã ã®è©Šæã«ã€ããŠã粟床ã®ç 究ãå®
æœããããããã®è©Šæããã€ããªãããããã«
ã€ããŠæž¬å®ãããããŠå埩ããå€ãæåŸ å€ãšæ¯èŒ
ãããå¹³åã®å埩å€ïŒrecovery volueïŒã¯100.8
ïŒ ã§ãã€ãã ãã€ããªããããããå¢å€§ããè¡æŒ¿ã®è©Šæ
ïŒã»ãŒ30ããã°ã©ã ïŒããªãªããã«ïŒã段éåžé
ãããããŠãã€ããªãããããã«ã€ããŠæž¬å®ã
ããåžéããè©Šæã¯ãæšæºæ²ç·å šäœãéããŠçŽç·
çã«å埩ããã äžã®ããŒã¿ã瀺ãããã«ããã®æ¹æ³ã¯0.3ã
40.0ããã°ã©ã ïŒããªãªããã«ã®ãã€ããªããã
ããã®ã¬ãã«ã«ãããŠãéåžžã«ç²ŸåºŠãé«ããæ
床ãé«ãããããŠåçŸæ§ãããã
äºåããŒã¿ã¯ãè¡æŒ¿ã®ïŒmlåœã0.3ã1.7ããã°ã©
ã ã®å€ãäžããã å€æ°ã®ã¢ãã»ã€ã«ã€ããŠå®éšå ããã³å®éšéã«
ãããŠãå€åçã¯10ïŒ ããå°ã§ããããšã瀺ãã
ãã0.1ããã°ã©ã ïŒããªãªããã«çšåºŠã«äœãå€
ãã0.0ããã°ã©ã ïŒããªãªããã«ã®æšæºãšåºå¥
ã§ããã çš®ã ã®éã®çŽç²ãªãã€ããªããããããå ã
ãïŒçš®é¡ã®å¥ã ã®è©Šæã«ã€ããŠã粟床ã®ç 究ãå®
æœããããããã®è©Šæããã€ããªãããããã«
ã€ããŠæž¬å®ãããããŠå埩ããå€ãæåŸ å€ãšæ¯èŒ
ãããå¹³åã®å埩å€ïŒrecovery volueïŒã¯100.8
ïŒ ã§ãã€ãã ãã€ããªããããããå¢å€§ããè¡æŒ¿ã®è©Šæ
ïŒã»ãŒ30ããã°ã©ã ïŒããªãªããã«ïŒã段éåžé
ãããããŠãã€ããªãããããã«ã€ããŠæž¬å®ã
ããåžéããè©Šæã¯ãæšæºæ²ç·å šäœãéããŠçŽç·
çã«å埩ããã äžã®ããŒã¿ã瀺ãããã«ããã®æ¹æ³ã¯0.3ã
40.0ããã°ã©ã ïŒããªãªããã«ã®ãã€ããªããã
ããã®ã¬ãã«ã«ãããŠãéåžžã«ç²ŸåºŠãé«ããæ
床ãé«ãããããŠåçŸæ§ãããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ç¬¬ïŒã«ãè¡æ¶²ã®è©Šæãéããåèšè©Šæäžã®ã
ãã³ãã³ãæå¶éã®ããã³ãã³æå¶å€ã§æå¶ãã
ãããŠè¡æŒ¿ãåèšè©Šæããåé¢ãã第ïŒã«ãåèš
è¡æŒ¿ã®è©Šæããã©ãžãªã€ã ãã¢ãã»ã€ç«¶åçµåæ¡
件äžã«ãååãªéã®ãã€ããªãããããã«å¯Ÿã
ãæäœããã³æŸå°æŽ»æ§ã§æšèãããã€ããªããã
ãããšæ¥è§Šããããã®åŸãæäœçµåãã€ããªã
ãããããçµåããªããã€ããªãããããã
ãåé¢ãããããŠæŸå°æŽ»æ§ã枬å®ããããšãããª
ããè¡æŒ¿äžã®ãã€ããªãããããã®æ¿åºŠã枬å®
ãã競åã©ãžãªã€ã ãã¢ãã»ã€æ³ã«ãããŠããã
ã³ãã³ã®æå¶å€ãšããŠãâPheâProâ
ArgCh2Clããã®å¡©é žä»å å¡©ããã®ããåæ°ŽçŽ é ž
ä»å å¡©ããã®é ¢é žä»å å¡©ããã³ãã®ã¯ãšã³é žä»å
å¡©ããæã矀ããéžã°ããæå¶å€ã䜿çšããããš
ãç¹åŸŽãšããæ¹æ³ã ïŒ è¡æŒ¿ããã³ããã€ãã§ååŠçããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ ãã¬ãŒãåéã®ãã¬ãŒãå€ããã³æã¿ã³ãã¯
å解éã®æã¿ã³ãã¯å解å€ããæå¶å€ã«ãããã
ã³ãã³ã®æå¶ã®éã«ãååšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®æ¹æ³ã ïŒ (1)âPheâProâArgCh2Clããã®å¡©é žä»å
å¡©ããã®ããåæ°ŽçŽ é žä»å å¡©ããã®é ¢é žä»å å¡©ã
ãã³ãã®ã¯ãšã³é žä»å å¡©ããæã矀ããéžã°ãã
ããã³ãã³ã®æå¶å€ã(2)ãã¬ãŒãå€ããã³(3)æã¿
ã³ãã¯å解å€ã®æ°Žæº¶æ¶²ãããªããåèšã®æå¶å€ã
ãã¬ãŒãå€ããã³æã¿ã³ãã¯å€ã®åã ã¯ãè¡æ¶²ãž
æ·»å ãããšãããã®æå³ããæ©èœãçºæ®ãããã
ã«ååãªéã§ååšãããããšãç¹åŸŽãšãããã€ã
ãªãããããã®çäœå€å®éã«é¢é£ããŠäœ¿çšãã
ããã³ãã³æå¶çšæååºè©Šè¬ã ïŒ ãã¬ãŒãå€ã¯EDTAãEGTAããã³ããã
ã®ãããªãŠã å¡©ããæã矀ããéžã°ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®è©Šè¬ã ïŒ æã¿ã³ãã¯å解å€ã¯ã¢ããããã³ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è©Šè¬ã ïŒ ãã¬ãŒãå€ã¯EDTAãEGTAããã³ããã
ã®ãããªãŠã å¡©ããæã矀ããéžã°ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®è©Šè¬ã ïŒ æŸå°æ§æšèãã€ããªããããã詊è¬ããã€
ããªãããããæäœè©Šè¬ããã³ãã€ããªããã
ããã®çäœå€å®éã«é¢é£ããŠäœ¿çšããããã³ã
ã³æå¶çšæååºè©Šè¬ãããªããåèšæååºè©Šè¬
ã¯ã(1)âPheâProâArgCh2Clããã®å¡©é žä»å
å¡©ããã®ããåæ°ŽçŽ é žä»å å¡©ããã®é ¢é žä»å å¡©ã
ãã³ãã®ã¯ãšã³é žä»å å¡©ããæã矀ããéžã°ãã
ããã³ãã³ã®æå¶å€ã(2)ãã¬ãŒãå€ãããã³(3)æ
ã¿ã³ãã¯å解å€ã®æ°Žæº¶æ¶²ãããªããåèšã®æå¶
å€ããã¬ãŒãå€ããã³æã¿ã³ãã¯å解å€ã®åã
ã¯ãè¡æ¶²ãžæ·»å ãããšããæå³ããæ©èœãçºæ®ã
ãã®ã«ååãªéã§ååšããããšãç¹åŸŽãšãããè¡
挿äžã®ãã€ããªãããããã®æ¿åºŠã®ã©ãžãªã€ã
ãã¢ãã»ã€çšããã±ãŒãžãã¹ããããã ïŒ ãã€ããªãããããã«å¯ŸããŠç¹ç°çã§ãªã
ãããã€ããªãããããã®æäœã«å¯ŸããŠç¹ç°ç
ã§ãã第ïŒæäœãããã«ååšããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®ããã±ãŒãžãã¹ããããã ïŒïŒ çŽç²ãªãã€ããªããããã詊è¬ã®æšæºãš
å¯Ÿç §è©Šæããå«ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ã
ãã±ãŒãžãã¹ããããã ïŒïŒ åèšè©Šè¬ã¯PHçŽïŒãçŽ10ã®æ°Žæº¶æ¶²ã§æäŸã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ããã±ãŒãžãã¹
ããããã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/284,152 US4438209A (en) | 1981-07-17 | 1981-07-17 | Radioimmunoassay for fibrinopeptide A |
| US284152 | 1981-07-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5824862A JPS5824862A (ja) | 1983-02-14 |
| JPH0220064B2 true JPH0220064B2 (ja) | 1990-05-08 |
Family
ID=23089057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57123731A Granted JPS5824862A (ja) | 1981-07-17 | 1982-07-14 | ãã€ããªãããããïœã®ã©ãžãªã€ã ãã¢ãã»ã€ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4438209A (ja) |
| EP (1) | EP0070478B1 (ja) |
| JP (1) | JPS5824862A (ja) |
| AT (1) | ATE18920T1 (ja) |
| AU (1) | AU8600082A (ja) |
| CA (1) | CA1196860A (ja) |
| DE (1) | DE3270252D1 (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8324167D0 (en) * | 1983-09-09 | 1983-10-12 | Wellcome Found | Diagnostic method and kit |
| US4722903A (en) * | 1983-11-14 | 1988-02-02 | New York Blood Center, Inc. | Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II |
| DE3400434A1 (de) * | 1984-01-09 | 1985-09-26 | Behringwerke Ag, 3550 Marburg | Bestimmung von fibrin mit fibrin-spezifischen antikoerpern |
| CA1313488C (en) * | 1986-03-12 | 1993-02-09 | Adair John Hotchkiss | Assay |
| US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
| US5453359A (en) | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
| JP2627644B2 (ja) * | 1988-06-14 | 1997-07-09 | éªå°ä¹³æ¥æ ªåŒäŒç€Ÿ | çµç¹åãã©ã¹ãããŒã²ã³æŽ»æ§åå åã®æž¬å®æ¹æ³åã³ãã®æž¬å®è©Šè¬ããã |
| NL8802710A (nl) * | 1988-11-04 | 1990-06-01 | Tno | Werkwijze voor het bepalen van een enzym en daarvoor geschikte kit en stof. |
| ES2090835T3 (es) * | 1992-02-17 | 1996-10-16 | Akzo Nobel Nv | Calibrador y su uso en un ensayo inmunologico. |
| US6238578B1 (en) * | 1996-12-09 | 2001-05-29 | Sherwood Services Ag | Method for dispensing separator gel in a blood collection tube |
| US7828741B2 (en) * | 2002-12-20 | 2010-11-09 | The Charlotte-Mecklenburg Hospital Authority | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| US20040138577A1 (en) * | 2002-12-20 | 2004-07-15 | Kline Jeffrey A. | Disposable hand-held device for collection of exhaled breath condensate |
| WO2004073497A2 (en) * | 2003-02-14 | 2004-09-02 | The Charlotte-Mecklenburg Hospital Authority | Device and method for collection of exhaled alveolar breath condensate |
| US7096681B2 (en) * | 2004-02-27 | 2006-08-29 | York International Corporation | System and method for variable speed operation of a screw compressor |
| US8016178B2 (en) * | 2009-03-31 | 2011-09-13 | Tyco Healthcare Group Lp | Surgical stapling apparatus |
| US8900822B2 (en) | 2011-11-21 | 2014-12-02 | Ethicon, Inc. | Fibrinogen assay |
| JP7464271B2 (ja) * | 2020-07-09 | 2024-04-09 | åœç«å€§åŠæ³äººå±±æ¢šå€§åŠ | åé¢è£ 眮åã³åé¢æ¹æ³ã䞊ã³ã«æ€æ»è£ 眮åã³æ€æ»æ¹æ³ |
-
1981
- 1981-07-17 US US06/284,152 patent/US4438209A/en not_active Expired - Fee Related
-
1982
- 1982-07-09 DE DE8282106164T patent/DE3270252D1/de not_active Expired
- 1982-07-09 CA CA000406946A patent/CA1196860A/en not_active Expired
- 1982-07-09 AT AT82106164T patent/ATE18920T1/de not_active IP Right Cessation
- 1982-07-09 EP EP82106164A patent/EP0070478B1/en not_active Expired
- 1982-07-14 JP JP57123731A patent/JPS5824862A/ja active Granted
- 1982-07-14 AU AU86000/82A patent/AU8600082A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US4438209A (en) | 1984-03-20 |
| DE3270252D1 (en) | 1986-05-07 |
| EP0070478A1 (en) | 1983-01-26 |
| JPS5824862A (ja) | 1983-02-14 |
| CA1196860A (en) | 1985-11-19 |
| EP0070478B1 (en) | 1986-04-02 |
| AU8600082A (en) | 1983-01-20 |
| ATE18920T1 (de) | 1986-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Merskey et al. | A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum | |
| Amiral et al. | Application of enzyme immunoassays to coagulation testing. | |
| US4438209A (en) | Radioimmunoassay for fibrinopeptide A | |
| US3995019A (en) | Diagnostic reagent system | |
| Amiral et al. | Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A | |
| Pradelles et al. | Immunometric assay of low molecular weight haptens containing primary amino groups | |
| US4298592A (en) | Double antibody separation method | |
| EP0713096A1 (en) | Immunoassay and kit for insulin-like growth factors | |
| US4622293A (en) | Iodothyronine immunoassays employing HMS as TBP blocking agent | |
| US4225784A (en) | Covalently bound biological substances to plastic materials and use in radioassay | |
| US4624916A (en) | Process and composition for the rapid quantitation of small levels of creative kinase-MB isoenzyme | |
| AU647431B2 (en) | An agent for improving the recovery of annexins | |
| US4081525A (en) | Radioimmunoassay of plasma steroids | |
| JP2004507745A (ja) | å¯æº¶æ§ãã£ããªã³ã®ã¢ãã»ã€æ³ | |
| Wehler et al. | The use of solid phase Clq and horseradish peroxidase-conjugated goat anti-IgG for the detection of immune complexes in human serum | |
| CA1093962A (en) | Bile acid competitive assay using protein binding inhibitor | |
| US4107284A (en) | Radioimmunoassay procedure using a stabilized complex | |
| Niemi et al. | Time-resolved immunofluorometric assay of sex-hormone binding globulin. | |
| JPS5928865B2 (ja) | å®å®åãããè¡å°æ¿å åïŒå ç«åææšæºæ¶² | |
| US4090846A (en) | Indirect latex test for determination of fibrinogen degradation products | |
| Mehany et al. | Immunoradiometric assay for the in-vitro determination of thyroid stimulating hormone in human serum and plasma using solid phase anti-TSH cellulose particles | |
| Poulsen | Simplified method for radioimmunoassay of enzyme systems: Application on the human renin-angiotensin system | |
| Braun et al. | Luminometric assays of seven acute-phase proteins in minimal volumes of serum, plasma, sputum, and bronchioalveolar lavage. | |
| Ghielmi et al. | Methodological effects on the quantitation of serum ferritin by radio-and enzymoimmunoassays | |
| Teni et al. | Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay. |